Advertisement
PRIMER
Fox transcription factors: from development to disease
Maria L. Golson, Klaus H. Kaestner
Development 2016 143: 4558-4570; doi: 10.1242/dev.112672

Abstract

Forkhead box (Fox) transcription factors are evolutionarily conserved in organisms ranging from yeast to humans. They regulate diverse biological processes both during development and throughout adult life. Mutations in many Fox genes are associated with human disease and, as such, various animal models have been generated to study the function of these transcription factors in mechanistic detail. In many cases, the absence of even a single Fox transcription factor is lethal. In this Primer, we provide an overview of the Fox family, highlighting several key Fox transcription factor families that are important for mammalian development.

Introduction

The forkhead (fkh) gene was originally identified in a random mutagenesis screen performed in Drosophila melanogaster (Weigel et al., 1989). This study showed that fkh is required for normal gut development, and that its absence results in a characteristic ʻforked head' appearance resulting from the homeotic transformation of the foregut into a head structure. Soon after this discovery, a number of related genes – termed Fox genes – were identified in multiple organisms, ranging from yeasts to humans.

The Drosophila Fkh protein is characterized by a winged-helix DNA-binding domain ∼100 residues long, termed the ‘forkhead box’. All Fox proteins share this distinctive DNA-binding domain but have divergent features and functions. Fox genes control a wide variety of biological functions and are broadly expressed both during development and in adult life. Their roles include, but are not limited to, the regulation of gastrulation (Ang and Rossant, 1994; Weinstein et al., 1994), stem cell and stem cell niche maintenance (Sackett et al., 2009; Aoki et al., 2016), the regulation of metabolism and cell cycle control (Hannenhalli and Kaestner, 2009). Indeed, Fox transcription factors are required for the normal specification, differentiation, maintenance and/or function of tissues such as the trophectoderm, liver, pancreas, ovaries, intestine, lung, kidney, prostate, brain, thyroid, skeletal and heart muscle, skeleton, vascular tissue and immune cells (Zhu, 2016).

Here, we first provide an overview of the Fox gene family and discuss how distinct Fox transcription factors regulate specific stages of development, tissue homeostasis and disease. Owing to their sheer number, we then concentrate on just four families: the FoxA factors and their role in the differentiation and maintenance of multiple cell types; FoxM1 and its control of the cell cycle; the FoxO group in regulating metabolism and longevity; and FoxP for its contribution to speech acquisition.

An overview of Fox transcription factors

The number of Fox genes currently cataloged varies widely among different organisms. Human and mouse both have 44, Drosophila 11, Caenorhabditis elegans 15, and Xenopus 45, the latter excluding alternate splice forms in all species and pseudogenes that were duplicated along with the rest of the Xenopus genome and expressed in exactly the same location as the original genes. Notably, Xenopus models contributed greatly to the initial description of Fox expression patterns in early embryogenesis (Pohl and Knöchel, 2005).

In mammals, Fox transcription factors are categorized into subclasses A to S (Fig. 1) based on sequence similarity within and outside of the forkhead box (Hannenhalli and Kaestner, 2009; Kaestner et al., 1999). In many cases, the homozygous deletion of just one Fox gene leads to embryonic or perinatal lethality and, in humans, mutations in or the abnormal regulation of Fox genes are associated with developmental disorders and diseases such as cancer (Halasi and Gartel, 2013; Li et al., 2015a; Wang et al., 2014b; Zhu et al., 2015; DeGraff et al., 2014; Halmos et al., 2004; Ren et al., 2015; Jones et al., 2015; Habashy et al., 2008), Parkinson's disease (Kittappa et al., 2007), autism spectrum disorder (Bowers and Konopka, 2012), ocular abnormalities (Acharya et al., 2011), defects in immune regulation and function (Mercer and Unutmaz, 2009) and deficiencies in language acquisition (Takahashi et al., 2009); see Table 1 for a comprehensive overview of Fox transcription factor expression patterns and their association with developmental disorders and disease.

Fig. 1.
Fig. 1.

Phylogenetic tree of mouse Fox family members. The entire sequences of mouse Fox transcription factors were aligned pairwise using Geneious software. The following parameters were employed: global assignment with free end gaps, the Jukes-Cantor genetics distance model, and unweighted pair-group method with arithmetic mean. Differences with other phylogenetic trees of Fox transcription factors are likely the result of grouping by homology to the FKH DNA-binding domain only. Scale indicates the relative number of amino acid changes between proteins.

View this table:
Table 1.

Summary of the functions of Fox family members in mice and roles in human disease

Distinct protein domains, expression patterns and post-translational modifications contribute to the divergent functions of Fox family members

Fox transcription factors bind a similar DNA sequence, albeit with different affinities, due to their highly conserved DNA-binding motif. How, then, do members of this large gene family have distinct roles? The divergent sequences outside of the conserved DNA-binding domain likely differentiate the function of these proteins, as do their distinct temporal and spatial gene activation patterns (Fig. 2).

Fig. 2.
Fig. 2.

The domain structure of selected Fox family members. Shown are the domain structures of mouse FoxA1-3, FoxM1, FoxO1, FoxO3, FoxO4, FoxO6 and FoxP1-4. TAD, transactivation domain; NRD, N-terminal repressor domain; NLS, nuclear localization signal; NES, nuclear export signal; ZF, zinc finger; LZ, leucine zipper.

The binding domains of FoxA transcription factors, for example, have structural similarity to linker histones H1 and H5 (Clark et al., 1993; Zaret et al., 2010). This feature allows FoxA transcription factors to access closed chromatin (Fig. 3), thus allowing the recruitment of alternative histones and facilitating the subsequent binding of other transcription factors at nearby sites (Cirillo et al., 2002; Li et al., 2012b; Updike and Mango, 2006). Indeed, genome-wide mapping of FoxA binding sites and nucleosome architecture in the mouse liver has shown that FoxA binds both nucleosome-bound and nucleosome-free DNA targets with the same recognition site (Li et al., 2011). For this reason, FoxA family members have been termed ‘pioneer’ transcription factors (Cirillo et al., 2002). In this role, they help specify cell types by giving tissue-specific transcription factors access to their binding sites (Iwafuchi-Doi and Zaret, 2016). They also help maintain cell identity by acting as ‘place holders’ or ‘bookmarks’ at genes that are normally shut off during cell division; after cytokinesis is complete, cell type-specific genes previously marked by FoxA can be easily reactivated (Caravaca et al., 2013). Accordingly, a number of studies have shown that FoxA transcription factors are expressed in early development and play crucial roles in the development and homeostasis of various cells and tissues (see below).

Fig. 3.
Fig. 3.

FoxA proteins function as pioneer factors. The schematic depicts how FoxA transcription factors are able to function as pioneer factors that control gene expression via their interaction with chromatin.

Because of their actions as pioneer factors, FoxA proteins are required to facilitate the binding of many other transcription factors to their targets. This is especially evident for several nuclear receptors, such as androgen receptor (AR), glucocorticoid receptor (GR) and estrogen receptor (ER). This was first shown for the interaction between FoxA1 and AR in the prostate (Gao et al., 2003), then for ER and FoxA1 (Hurtado et al., 2011; Ross-Innes et al., 2012; Carroll et al., 2005; Lupien et al., 2008) and for FoxA2 and GR (Zhang et al., 2005). The consequences of this cooperative binding, particularly in the context of cancer, are discussed in detail below.

FoxM1 is best known for its role in regulating the cell cycle. Its forkhead DNA-binding domain (FHD) shares only 18% sequence identity with that of FoxA1, and FoxM1 has lower affinity for the forkhead consensus binding site than other Fox proteins (Littler et al., 2010). Some investigators have shown that, instead of directly interacting with the DNA of its proliferative targets, FoxM1 attaches to proteins in the DREAM complex – a larger conglomeration of proteins that prevents the transcription of proliferative targets in the quiescent state, but promotes expression of the same targets during the cell cycle (Chen et al., 2013). However, other reports have demonstrated direct binding of FoxM1 to its targets (Sanders et al., 2013).

Given its crucial function in cell cycle control, FoxM1 expression and activity must be tightly regulated. Indeed, Foxm1 mRNA and protein are only usually expressed during the cell cycle (Korver et al., 1997). The activity of FoxM1 is also tightly controlled by several post-transcriptional mechanisms (reviewed by Golson et al., 2010): (1) FoxM1 is generally excluded from the nucleus, but phosphorylation by MAPK induces its translocation; (2) an intramolecular repressive domain inhibits the binding of FoxM1 to DNA until phosphorylation by Chek2 (Chk2); (3) FoxM1 only recruits co-factors for gene transactivation when phosphorylated by Cdk1/2; and (4) FoxM1 is targeted to the proteasome when phosphorylated by a presently unknown kinase.

Like FoxM1, the activity of FoxO proteins – a group of proteins that inhibit the cell cycle and regulate lifespan and metabolism – is regulated post-translationally. Phosphorylation by Akt, for example, leads to the nuclear exclusion of FoxO1 and sequestration away from DNA by the 14-3-3 scaffolding protein (Tzivion et al., 2011). Unlike many other Fox transcription factors, FoxO factors contain both a nuclear export signal (NES) and a nuclear localization signal (NLS) (Tzivion et al., 2011). FoxO proteins help to activate transcription of their targets by recruiting the SWI/SNF chromatin remodeling complex (Riedel et al., 2013). These transcriptional targets include antioxidants, cell cycle inhibitors and metabolic genes; in many ways, FoxO proteins act counter to FoxM1.

Although most Fox transcription factors are strictly transcriptional activators, some, such as FoxP, have dual activator and repressor functions; indeed, members of the FoxP family are thought to act primarily as repressors (Zuo et al., 2007; Shu et al., 2001; Li et al., 2004a). FoxP family members can bind as homo- or heterodimers through their leucine zipper and zinc finger domains, and this interaction is required for FoxP family members to repress their targets, perhaps because a conformational change occurs upon binding that allows a portion of the N-terminal domain to recruit co-repressors such as histone deacetylases, the lysine acetyltransferase TIP60 (Kat5), and the SMRT complex (Li et al., 2007; Wang et al., 2003; Lal and Bromberg, 2009; Jepsen et al., 2008). The proline-rich track within the N-terminus of FoxP3 is essential for its function as a repressor (Xie et al., 2015), and this suggests that the glutamine-rich tracts in FoxP1, 2 and 4 are essential for their function. The structure of FoxP proteins when dimerized prevents them from binding the same strand of DNA on adjacent sites, suggesting that FoxP factors could also act to bring distal chromatin regions together (Stroud et al., 2006). Like FoxM1, recent reports have suggested that FoxP factors act in some cases by binding to other proteins rather than via direct interactions with DNA (Xie et al., 2015).

In addition to divergent protein domains, individual Fox factors have different binding partners and co-factors, which can influence both the specific DNA targets that are contacted and their downstream effects on transcriptional activity (Li et al., 2015b). Finally, many Fox transcription factors are expressed in distinct spatiotemporal patterns, allowing them to carry out distinct functions. However, it should be noted that, despite the well-known distinct roles of various families of Fox transcription factors, it is becoming clear that many of them regulate the same processes.

The FoxA family: regulators of development, differentiation and cell identity

Mammalian FoxA transcription factors were first identified for their DNA-binding properties in rat liver nuclear extracts and were thus originally named hepatocyte nuclear factor 3 (HNF3) α, β and γ (Costa et al., 1989). Of all mammalian Fox genes, Foxa2 shares the most homology with the original fkh gene discovered in Drosophila. Its homolog in the nematode C. elegans is pha-4 and, notably, studies of pha-4 mutants have helped further our understanding of FoxA function by identifying FoxA targets (Gaudet and Mango, 2002), establishing their interactions with nuclear hormone receptors (Ao et al., 2004), demonstrating the recruitment of RNA polymerase II (Hsu et al., 2015) and the histone variant H2A.Z (Updike and Mango, 2006), and characterizing the regulation of PHA-4 by the TOR pathway.

The expression of FoxA factors

In mammals, FoxA1, 2 and 3 exhibit overlapping but distinct expression patterns in a variety of developing and mature tissues (Friedman and Kaestner, 2006). In the mouse, Foxa2 is the first member of the FoxA family to be expressed. At embryonic day (E) 6.5, Foxa2 expression can be detected in the primitive streak and in the node, both of which are important for gastrulation. By E7.5, Foxa2 is expressed in the mesoderm and definitive endoderm (Monaghan et al., 1993; Ang et al., 1993). Its expression is then maintained in endoderm-derived tissues, such as the pancreas, liver, thyroid, prostate and lung, throughout development and in adulthood (Friedman and Kaestner, 2006), and is also observed in ectoderm-derived neural tissues, such as the ventral midbrain, including in dopaminergic neurons and the hypothalamus (Besnard et al., 2004).

During early embryogenesis, the expression of Foxa1 is similar to that of Foxa2, but following a short temporal delay. For example, Foxa1 can first be detected at E7.0 in the primitive streak, and then later in the notochord, neural plate, floor plate and neural tube (Monaghan et al., 1993). However, the expression of Foxa1 and of Foxa2 differ in the adult. Although Foxa1 is initially highly expressed in the developing pancreas, its expression falls to <10% of Foxa2 levels in alpha, beta and acinar cells in the adult pancreas (Bramswig et al., 2013). In addition, Foxa1 is more widely expressed than Foxa2 in several adult tissues, including the respiratory system, brain and gastrointestinal tract. Foxa1 is also expressed in some tissues that lack FoxA2 entirely, such as male reproductive organs, the ureter and bladder (Friedman and Kaestner, 2006).

The expression of Foxa3 is more restricted than that of Foxa1 or Foxa2, and is more specific to the foregut endoderm than other family members. Foxa3 expression can first be detected at E8.5 and is maintained strongly in the liver but also in the pancreas and intestine throughout adulthood (Monaghan et al., 1993). It is the mostly highly expressed FoxA transcription factor in the adult liver (Kaestner et al., 1994).

The role of FoxA transcription factors

The earlier expression of FoxA2 compared with FoxA1 and FoxA3 is reflected in the severity of phenotypes in mice lacking these factors. Mice null for Foxa2 die between E10 and E11, exhibiting defects in all three germ layers (Weinstein et al., 1994; Ang and Rossant, 1994). Heterozygotes for Foxa2 are viable but display a Parkinson's-like phenotype following aging (Kittappa et al., 2007). In contrast to Foxa2 null mice, those lacking Foxa1 survive until after birth, displaying lethality between postnatal day (P) 2 and 12 due to hypoglycemia and defects in kidney function (Behr et al., 2004; Kaestner et al., 1999); the hypoglycemia is likely to result from deficiencies in glucagon secretion, while the dehydration stems from abnormal kidney development (Behr et al., 2004; Kaestner et al., 1999). These mice also display defects in prostate morphogenesis (Gao et al., 2005). As might be expected from its limited expression pattern, among the FoxA family mice deficient for Foxa3 have the mildest phenotype. They are viable with a normal lifespan but do, however, display hypoglycemia after a prolonged fast because of defects in hepatic glucose production (Shen et al., 2001).

Since the embryonic lethality of Foxa2−/− mice precludes analysis of the role of FoxA2 in the organogenesis and function of many tissues, mice with conditional deletions of Foxa2 have been derived. Studies of these mutants reveal that FoxA2 on its own is not required for normal liver differentiation (Sund et al., 2000), although defects in lung morphogenesis are seen (Wan et al., 2004). In addition, severe defects in pancreatic islet formation and alpha and beta cell maturation that lead to alterations in glucose homeostasis are observed (Sund et al., 2000; Lantz et al., 2004). Interestingly, mice expressing an activated form of FoxA2 in neurons display an orexigenic (i.e. a stimulated appetite) phenotype (Silva et al., 2009). Although off-target effects of this mutated protein cannot be excluded, this study implicates FoxA2 in yet more aspects of metabolic regulation, namely food intake and energy output.

Cooperativity and compensation among FoxA transcription factors

The conditional deletion of genes encoding individual FoxA transcription factors revealed little requirement for any one FoxA family member in the liver (Lee et al., 2005b; Kaestner et al., 1999; Shen et al., 2001). Gross pancreatic morphology was also unaffected when only one FoxA transcription factor was missing (Lee et al., 2005b; Kaestner et al., 1999). These studies suggest either that FoxA family members are dispensable in these organs or, alternatively, that they can compensate for each other. Both in vivo and in vitro studies suggest that the latter possibility is likely: both FoxA1 and FoxA2 transcription factors must be suppressed to abolish expression of Muc2, which encodes a protein important for intestinal function (van der Sluis et al., 2008), and both Foxa1 and Foxa2 are upregulated in Foxa3 null livers (Shen et al., 2001). In addition, several different analyses using the conditional, simultaneous deletion of Foxa1 and Foxa2 demonstrated that these two transcription factors can compensate for each other in a number of tissues. For example, their combined absence results in complete liver agenesis (Lee et al., 2005a), near-complete pancreatic agenesis (Gao et al., 2008), and altered allocation of enteroendocrine cells within the intestine (Ye and Kaestner, 2009), but, as outlined above, deletion of only one FoxA transcription factor leads to a less severe phenotype in these tissues. Finally, mice with a late-gestation deletion of both Foxa1 and Foxa2 demonstrate upregulation of Foxa3, with FoxA3 also being observed to bind FoxA targets in the double-null animal that were bound only by FoxA1 and FoxA2 in wild-type mice (Iwafuchi-Doi et al., 2016).

FoxM1: a key cell cycle control factor

FoxM1 was identified nearly simultaneously by three groups and hence was originally given three names: Trident (Korver et al., 1997), hepatocyte nuclear factor 3/fork head homolog 11 (Ye et al., 1997) and WIN (winged helix protein in the INS1 cell line) (Yao et al., 1997). All three groups identified FoxM1 by homology to FoxA proteins, but whereas the Clevers group discovered it within the thymus, the Costa lab cloned it from the colon carcinoma cell line Caco-2, and the Wong group identified it in a cell line derived from an insulinoma.

FoxM1 is widely recognized for its role in driving the cell cycle (Fig. 4). Its direct transcriptional targets function at both the G1/S and G2/M transitions, as well as during karyokinesis and cytokinesis (reviewed by Wierstra, 2013; Wierstra and Alves, 2007). Accordingly, FoxM1 expression is mostly confined to actively replicating cells; its expression is thus broad in embryos and declines in differentiated tissue as well as with age (Ye et al., 1997).

Fig. 4.
Fig. 4.

The role of FoxM1 in cell cycle regulation. FoxM1 regulates various factors involved in cell cycle regulation. No evidence for FoxM1 regulation exists for those cell cycle proteins shown in gray. Cyclin D2, but not A and E, is regulated by FoxM1. p16 is also known as Cdkn2a; SCF as Kitl; p21/p27 as Cdkn1a/Cdkn1b; and survivin as Birc5.

FoxM1 exists in various genera and species, including Xenopus, Danio, Mus, Rattus and H. sapiens, but not in C. elegans or Drosophila. The role of FoxM1 in Drosophila and C. elegans might be filled by other forkhead transcription factors, but at this time the only reports associating forkhead with proliferation in these two organisms is the increased replication in the absence of FoxO homologs. In humans, although one FOXM1 gene exists, splice variants produce three different FOXM1 proteins: FOXM1A, FOXM1B and FOXM1C. Both FOXM1B and FOXM1C are transcriptional activators, whereas FOXM1A is a transcriptional repressor. In mice, only one FoxM1 protein splice variant is produced; it is most similar to human FOXM1B and is likewise a transactivator.

The crucial role of FoxM1 in development is highlighted by studies perturbing its expression. For example, mice lacking FoxM1 display embryonic lethality between E14.5 and E16.5 due to failed liver and heart expansion (Krupczak-Hollis et al., 2004). Mice with conditional deletions of Foxm1 display profound proliferation defects in tissues such as the liver (Krupczak-Hollis et al., 2004), heart (Bolte et al., 2011), pancreas (Zhang et al., 2006), intestine (Yoshida et al., 2007), lungs (Kalin et al., 2008) and smooth muscle (Ustiyan et al., 2009). Furthermore, the early deletion of Foxm1 in either the heart (Bolte et al., 2011) or liver (Krupczak-Hollis et al., 2004) results in embryonic lethality, whereas mice lacking Foxm1 in smooth muscle cells (Ustiyan et al., 2009) or in the lung epithelium (Kalin et al., 2008) die perinatally.

Interest in FoxM1 was fueled by its prominent role in cancer. FoxM1 is highly expressed in a variety of tumor types and is associated with increased tumor aggressiveness (Laoukili et al., 2007). However, mouse models suggest that FoxM1 elevation by itself is not an initiating event in carcinogenesis. Mice constitutively expressing human FOXM1B in all tissues do not spontaneously develop tumors at least until 12 months of age (Kalinichenko et al., 2003; Wang et al., 2002; Yoshida et al., 2007). However, increased expression of FOXM1B, in addition to initiating mutations, leads to larger, more vascularized and more metastatic tumors (Yoshida et al., 2007; Kalinina et al., 2003). Conversely, mice lacking FoxM1 or with inhibited FoxM1 function in the tissue of interest show a reduced tumor load compared with controls when treated with carcinogens (Yoshida et al., 2007; Gusarova et al., 2007). Similar results have been observed in the lung, where increased FoxM1 activity hastens lung tumor growth in mice with induced Kras expression (Wang et al., 2010), while its absence inhibits lung tumorigenesis mediated by Kras (Wang et al., 2014a). Given this link between FoxM1 and tumor progression, anti-FoxM1 agents are being explored as potential cancer therapeutics (Box 1).

Box 1. Anti-FOXM1 agents as potential cancer therapies

Owing to the association of FOXM1 with aggressive tumors, and because of direct evidence highlighting the importance of FoxM1 in tumor progression in mice, there is intense interest in developing anti-FOXM1 agents as therapies for a variety of cancers. The downregulation of FOXM1 by siRNA in vitro decreases DNA replication as well as angiogenic and metastatic potential (Wang and Gartel, 2011; Wu et al., 2010; Halasi and Gartel, 2012; Halasi et al., 2013). A number of proteasome inhibitors have been shown to decrease FOXM1 levels, probably by stabilizing an unidentified negative regulator of FOXM1 (Gartel, 2010), and many of these inhibitors are currently used in cancer treatments; most of their effects are likely to be due, at least in part, to FOXM1 downregulation. However, these drugs are also associated with serious side effects (Adams et al., 1999), so more specific inhibitors of FOXM1 have been sought. Recently, a high-throughput screen identified a small molecule, FDI-6, that makes direct contact with the DNA-binding domain of FOXM1, blocks the interactions of FOXM1 with its transcriptional targets, and suppresses the expression of those targets (Gormally et al., 2014). FDI-6 is specific enough that it does not affect the binding or function of other Fox transcription factors, and it also does not affect proteasomal activity. This novel molecule thus has exciting potential therapeutic applications for a variety of cancers.

FoxM1 also appears to be implicated in aging. FoxM1 levels decline with age in multiple tissues, and this decrease is accompanied by a decline in both baseline proliferation and replicative potential. The reactivation of FoxM1 activity in aged hepatocytes and pancreatic beta cells was able to rejuvenate replication in these tissues (Golson et al., 2015; Wang et al., 2002). In addition, transplanted aged FoxM1b-expressing hepatocytes were equally successful in repopulating recipient livers as hepatocytes from young mice (Brezillon et al., 2007). Currently, the transplantation of hepatocytes or beta cells can be used to treat liver diseases or type 1 diabetes, respectively; however, a shortage of both of these cell types for transplantation prevents their widespread application. Inducing FoxM1 expression transiently ex vivo could, therefore, expand the availability of transplantation-quality donor tissue by rejuvenating older donor tissue. However, as is the case for other proteins involved in the cell cycle, the benefits of activating or attenuating FoxM1 activity must be carefully considered. Drug treatments are currently not targeted to any one tissue, and activating FoxM1 endogenously to rejuvenate the replicative potential in a tissue of interest without targeting it to a specific cell type could potentially cause existing malignancies to become more prone to growth or metastasis. Conversely, inhibiting FoxM1 in cancer therapy could have negative impacts in tissues that are likely to require FoxM1 activity and exhibit high cellular turnover, such as the intestine.

FoxO factors: from cell cycle control to metabolism and longevity

FoxO proteins play multiple crucial roles: they regulate the cell cycle, apoptosis, metabolism and lifespan. Recently, interest in FoxO proteins has also been spurred on by their functions in mediating insulin and insulin-like signaling (Fig. 5) (reviewed by Golson et al., 2010). In short, insulin binding to the insulin receptor causes phosphorylation of insulin receptor substrate 1/2 (IRS1/2), resulting in a phosphorylation signaling cascade that involves phosphoinositide 3-kinase and Akt, and ultimately leads to the phosphorylation of FoxO. In the absence of insulin signaling, FoxO proteins reside in the nucleus; however, active insulin signaling causes them to translocate to the cytoplasm, where they are no longer able to bind or transactivate their targets. In addition, Akt-phosphorylated FoxO proteins are stabilized in the cytoplasm through interactions with 14-3-3 scaffolding proteins (reviewed by Tzivion et al., 2011). This stabilization can be disrupted by the phosphorylation of 14-3-3 by Jun kinase and the dephosphorylation of FoxO by protein phosphatase 2A. FoxO protein stability is also regulated by ERK1/2 (Mapk3/1), which phosphorylate FoxO proteins and target them for degradation (Yang et al., 2008).

Fig. 5.
Fig. 5.

FoxO regulation in response to insulin signaling in mammals. The binding of growth factors to their receptors triggers a phosphorylation signaling cascade involving phosphoinositide 3-kinase (PI3K), phosphatidylinositol (4,5) bisphosphate (PIP2), phosphatidylinositol (3,4,5)-trisphosphate (PIP3), pyruvate dehydrogenase kinase (PDK) and Akt that ultimately results in the phosphorylation of FoxO. This phosphorylation confines FoxO to the cytoplasm. In the absence of growth factor signaling, including that of insulin, FoxO is thus present in the nucleus, where it upregulates anti-stress genes and cell cycle inhibitors. FoxO also regulates gluconeogenic genes in the mammalian liver to protect from hypoglycemia. Modified from Golson et al. (2010).

FoxO in C. elegans

The role of FoxO proteins in longevity was first revealed by studies in the nematode C. elegans. During periods of high stress, such as a low food supply, C. elegans enter a ‘dauer’ state that allows them to survive and also extend their lifespan (reviewed by Fielenbach and Antebi, 2008). In such times of nutrient shortage, expression of insulin receptor homologs such as DAF-2 is low. The sole C. elegans FoxO homolog, DAF-16, is therefore not phosphorylated and is thus able to enter the nucleus and transactivate its targets, a full list of which was recently published (Kaletsky et al., 2016). The effect of DAF-16 on longevity is primarily manifested in the intestine (Murphy et al., 2007; Libina et al., 2003), and its effects on lifespan are likely to be related to the regulation of genes involved in countering oxidative and thermal stress (Nemoto and Finkel, 2002).

DAF-16 also regulates multiple neuronal processes, including many different learning processes, sleep, morphology maintenance and axon regeneration (Kauffman et al., 2010; Tank et al., 2011; Toth et al., 2012; Murakami et al., 2005; Byrne et al., 2014; Nagy et al., 2014). A recent study delineated the neural targets of DAF-16 in C. elegans by comparing the transcriptomes of neurons that had been FACS sorted from wild type and insulin signaling-deficient (daf-16;daf-2) mutants (Kaletsky et al., 2016). Since many FoxO targets are conserved from C. elegans to humans (Webb et al., 2016), it has been proposed that understanding the mechanisms by which FoxO regulates aging in the nematode might provide a basis for extending human lifespan. However, given the fundamental differences in the aging process between these very distantly related species, caution is warranted.

FoxO in mammals

Mammals have four FoxO proteins: FoxO1, FoxO3, FoxO4 and FoxO6. FoxO6 shares the least sequence homology with other FoxO family members. FoxO1 is the most thoroughly studied of the family but, like FoxO1, FoxO3 and FoxO4 have roles in regulating lifespan and metabolism and in mediating cell cycle arrest.

Regulation of metabolism by FoxO1

FoxO1 is the most highly expressed FoxO family member in insulin-responsive tissues such as the liver, adipose tissue and skeletal muscle (Armoni et al., 2006). Consistent with this broad expression pattern, FoxO1 regulates multiple metabolic processes. In the liver, FoxO1 contributes to the activation of gluconeogenic targets (Nakae et al., 2002; Matsumoto et al., 2007; Titchenell et al., 2015; Haeusler et al., 2010), and deleting one copy of Foxo1 corrects the insulin resistance phenotype in insulin receptor-deficient mice (Nakae et al., 2002). In skeletal muscle, FoxO1 appears to control whether carbohydrates or lipids are used as fuel by regulating the expression of genes such as those encoding pyruvate dehydrogenase kinase and lipoprotein lipase (Bastie et al., 2005), while in adipose tissue it may protect white fat cells from the dysfunction associated with obesity (Subauste and Burant, 2007). FoxO1 is also a key player in regulating the differentiation of adipose tissue and skeletal muscle (Gross et al., 2008).

In addition to liver, muscle and adipose tissue, FoxO1 is highly expressed in insulin-secreting beta cells, where it may act in a protective capacity in times of stress. Several reports have indicated that FoxO proteins activate the expression of antioxidant enzymes, and FoxO1 protects beta cells against the effects of reactive oxygen species, since it and family members activate the expression of antioxidant enzymes (Kitamura et al., 2005; Kops et al., 2002; Nemoto and Finkel, 2002). FoxO1 has also been implicated in preventing beta cell de-differentiation during stress by suppressing neogenic genes, such as the early endocrine development factor neurogenin 3 (Neurog3), which is not normally expressed in the adult endocrine pancreas (Talchai et al., 2012). Protection by FoxO1 occurs in the presence of many metabolic stressors, such as multiple pregnancies, chemical ablation of beta cells, and when insulin resistance is conferred by leptin receptor (Lepr) deficiency. However, a contradictory study of mice deficient for Lepr in all tissues or for FoxO1 specifically in beta cells indicates that FoxO1 promotes the expression of the same genes (Kobayashi et al., 2012). The reason for this discrepancy is not apparent at this time, and both studies demonstrated more severe hyperglycemia in Lepr−/− mice lacking FoxO1 compared with those with FoxO1 expression. Previous work demonstrating the induction of the beta cell maturity marker MafA by FoxO1 also supports a role for FoxO1 in preventing de-differentiation (Kitamura et al., 2005). FoxO1 may thus protect beta cells from dysfunction during the period of insulin resistance that precedes type 2 diabetes.

A second role proposed for FoxO1 is in regulating beta cell mass. FoxO proteins have been shown to upregulate cell cycle inhibitors (Martins et al., 2015). In mice lacking one copy of the insulin receptor in all tissues, beta cell proliferation is reduced compared with that in wild-type mice, but deletion of one copy of Foxo1 partially rescues beta cell division (Nakae et al., 2002). Conversely, Foxo1 overexpression attenuates the increased beta cell mass normally observed in mice overexpressing the insulin receptor (Okamoto et al., 2006). However, contradictory reports have called the generality of these observations into question. Mice lacking Foxo1 either in beta cells or throughout the entire pancreas show no increase in beta cell proliferation either on a chow or high-fat diet (Kobayashi et al., 2012), and mice overexpressing FoxO1 fed a high-fat diet actually showed increased beta cell proliferation (Zhang et al., 2016). These results suggest that FoxO1 might inhibit beta cell replication only when the insulin receptor is completely absent, which is a unique and rare state.

FoxO in mammalian longevity

Like DAF-16 in C. elegans, FoxO transcription factors together with calorie restriction and insulin signaling have been reported to regulate lifespan in rodents (Mulvey et al., 2014; Shimokawa et al., 2015). For example, decreased insulin signaling correlates with human longevity (Kojima et al., 2004; Pawlikowska et al., 2009), as do several genetic variants in FOXO3 (Willcox et al., 2008; Pawlikowska et al., 2009; Flachsbart et al., 2009; Li et al., 2009). In mice, FoxO3, but not FoxO1, is required for an expanded lifespan due to calorie restriction (Shimokawa et al., 2015). However, a meta analysis calls this conclusion for calorie restriction into question (Swindell, 2012). First, in some mouse strains, life expectancy was actually shortened in cohorts with calorie restriction (Liao et al., 2010; Swindell, 2012). Second, ad libitum fed controls might not be an ideal comparison for rodents with calorie restriction; ad libitum access to normal chow leads to weight gain and associated detrimental health effects (Sohal and Forster, 2014). Mixed results have also been reported for non-human primates (Colman et al., 2009; Bodkin et al., 2003; Mattison et al., 2012), and studies correlating calorie restriction and longevity are hard to perform accurately in humans and thus far have been inconclusive (Heilbronn and Ravussin, 2003).

At present, the mechanisms by which FoxO3 or other FoxO transcription factors influence lifespan, if at all, in humans is still unknown. However, one could envision that the multiple processes in which FoxO plays a role, such as stress resistance, cell cycle regulation and control of apoptosis, could pleiotropically influence healthy aging.

The FoxP family: language acquisition and cognitive function

In mammals there are four FoxP genes (Foxp1-4), and the transcription factors that they encode have been shown to play a role in the development of multiple cell types, including cardiomyocytes (Wang et al., 2004), neurons (Shu et al., 2005), lung epithelial secretory cells (Li et al., 2012a) and regulatory T-cells (Fontenot et al., 2003). Accordingly, FoxP null mice display varying phenotypes. Foxp1−/− (Wang et al., 2004) and Foxp4−/− (Li et al., 2004b) mice display embryonic lethality by E14.5 due to a thinning of the cardiac ventricular myocardium. Foxp2−/− mice display severe cerebellar defects and motor impairment; they usually die by 3 weeks of age (Shu et al., 2005). Foxp3−/− mice have a defect in regulatory T-cells and escalated lymphocyte proliferation rates; these combined abnormalities lead to an immune attack on multiple cells and organs, including pancreatic beta cells, resulting in a disease resembling type 1 diabetes (Fontenot et al., 2003), and Foxp3−/− mice die by 4 weeks of age (Fontenot et al., 2003). Tissue-specific deletions of FoxP factors also result in developmental defects. For example, mice with a deletion of Foxp1 in neurons are viable but display a morphological change in the striatum and hippocampus (Bacon et al., 2015).

Members of the FoxP family, notably FoxP1 and FoxP2, have also generated interest because of their roles in regulating cognitive development processes such as speech acquisition. FoxP2 was the first of this transcription factor family to be associated with language deficits (Lai et al., 2001) but, more recently, FoxP1 has also been implicated in speech development (Horn et al., 2010; Hamdan et al., 2010). Mutations in both FOXP1 and FOXP2 are associated with other cognitive dysfunctions, such as autism spectrum disorder (ASD) and intellectual disability (Bacon and Rappold, 2012). However, disorders associated with the two genes do not have completely overlapping symptoms, indicating that the two transcription factors might regulate different but related brain functions. For example, language deficits caused by alterations in Foxp2 are generally accompanied by deficits in orofacial movements, whereas impairments in language acquisition associated with Foxp1 variants are always accompanied by another cognitive impairment (Bacon and Rappold, 2012). Currently, no known connections between cognitive function and Foxp3 or Foxp4 exist.

How FoxP1 and FoxP2 contribute to neural function has also been investigated in animal models. Normally, mouse pups subvocalize when separated from their mother; Foxp2−/− pups do not exhibit this behavior, and Foxp2+/− pups show a reduction (Shu et al., 2005). No alterations in vocalization were reported for mice with a brain-specific deletion of Foxp1; however, these mice exhibit abnormal cognitive and social behavior, echoing phenotypes in patients with FOXP1 mutations (Bacon et al., 2015).

In a striking example of evolutionary conservation, FoxP1 function has been studied in songbirds. Mouse subvocalization is innate, whereas human speech and birdsong share the necessity that they must be learned from older members of the species. After a FOXP2 mutation was identified in a family with inherited impaired speech acquisition, the expression patterns of Foxp1 and Foxp2 were investigated in zebra finch brains (Teramitsu et al., 2004). Similarities in the expression patterns of Foxp1 and Foxp2 were observed between songbird and human brains, and Foxp2 was upregulated during the period when adolescent finches actively learned song patterns (Haesler et al., 2007). When Foxp2 gene activity was suppressed during adolescence, the affected birds copied their tutors with less precision than controls. These studies highlight a remarkable conservation of function in Fox transcription factor function between disparate species.

Shared and cooperative roles for Fox transcription factors

Although Fox transcription factors have distinct expression patterns and are known for fulfilling different roles in regulating biological processes, many of these transcription factors often have similar roles. As mentioned above, FoxA and FoxO transcription factors both regulate glucose homeostasis and metabolism. However, FoxM1 (Golson et al., 2015) as well as FoxP1, FoxP2 and FoxP4 (Spaeth et al., 2015) were recently reported to contribute to these processes as well. Another overlap is the action of these proteins as pioneer factors; both FoxO (Hatta and Cirillo, 2007) and FoxE (Cuesta et al., 2007), in addition to members of the FoxA family, can act in this capacity.

Notably, a number of Fox transcription factors have been implicated in regulating cell proliferation. FoxM1 and FoxO, for example, have long been known to have opposing roles in the cell cycle and tumorigenesis. Many other Fox transcription factors, such as FoxC2, FoxE3, FoxF1, FoxF2, FoxN1 and FoxN3, also regulate proliferation (Tuteja and Kaestner, 2007b; Tuteja and Kaestner, 2007a). FoxA2 acts as a tumor suppressor by maintaining a differentiated state and decreasing metastasis in liver, lung and breast tissue (Tang et al., 2011; Wang et al., 2014b; Zhang et al., 2015), while FoxA1 acts as an oncogene in breast and prostate cancer (Yamaguchi et al., 2008; Imamura et al., 2012). Remarkably, in the liver, the FoxA proteins act as both repressors and promoters of hepatic carcinogenesis, dependent on the sex of the animals (Li et al., 2012c). Thus, while male mice deficient for both FoxA1 and FoxA2 develop fewer tumors, the situation is opposite in female mice, demonstrating the key role of FoxA factors in the action of the sex steroid hormone receptors.

Diverse Fox transcription factors also interact with estrogen receptor α (ERα; also known as ESR1) to regulate multiple aspects of tumorigenesis. In the MCF7 human breast cancer cell line, FOXA1 acts as a pioneer transcription factor and opens up chromatin, allowing the nearby binding of ERα (Hurtado et al., 2011). At cell cycle loci, FOXM1 can then displace FOXA1 and transactivate cell cycle genes. FOXM1 binds 70% of the same genes as FOXA1 in this breast cancer line (Sanders et al., 2013). Interestingly, FoxO transcription factors act as ERα status-dependent tumor suppressors in breast cancer. In ERα-positive breast cancer, FOXO3 is associated with less invasiveness, whereas in ERα-negative breast cancer, FOXO3 is associated with more invasive tumors (Sisci et al., 2013). Finally, the FoxA homolog PHA-4 contributes to increased longevity in C. elegans (Panowski et al., 2007). As with FoxO proteins, higher nutrient levels lead to the repression of PHA-4 activity and a decreased lifespan, and in this function FoxA is negatively regulated by the TOR pathway (Sheaffer et al., 2008).

Because many Fox transcription factors are required for life, they clearly are unable to compensate completely for each other. However, their highly related consensus binding sites suggest that they can substitute for each other to some degree. It is likely that some of the overlapping roles for Fox proteins reflect differences in expression patterns, such that one Fox protein might perform the same role in the gut that another performs in neural tissues. In other cases, it is likely that distinct Fox proteins act in somewhat divergent ways at the same loci, for example by recruiting different co-factors.

Conclusions

Fox transcription factors are remarkably well conserved DNA-binding proteins and regulators of gene expression. In mammals, diverse Fox factors share multiple roles. This ancient class of transcription factors contributes to the control of all aspects of development, from before gastrulation to the prevention of adult disease. Indeed, Fox transcription factors constitute a promising drug target considering their involvement in so many diseases. However, because they are transcription factors and hence are not accessible at the cell surface, or even generally in the cytoplasm, they have thus far largely remained unalterable, whether at the expression or activity level. Future studies to target Fox transcription factors should be aimed in the following directions: (1) the cell type-specific delivery of a drug payload that would be internalized; (2) gaining an understanding and then targeting of the regulatory mechanisms of Fox expression; (3) the identification and targeting of Fox target genes. Such approaches will, no doubt, further our understanding of Fox transcription factors in human biology and disease.

Footnotes

  • Competing interests

    The authors declare no competing or financial interests.

  • Funding

    This work was supported by the National Institutes of Health (DK-P01-049120 to K.H.K.). Deposited in PMC for release after 12 months.

References

  1. ↵
    1. Acharya, M.,
    2. Huang, L.,
    3. Fleisch, V. C.,
    4. Allison, W. T. and
    5. Walter, M. A.
    (2011). A complex regulatory network of transcription factors critical for ocular development and disease. Hum. Mol. Genet. 20, 1610-1624. doi:10.1093/hmg/ddr038
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Adams, J.,
    2. Palombella, V. J.,
    3. Sausville, E. A.,
    4. Johnson, J.,
    5. Destree, A.,
    6. Lazarus, D. D.,
    7. Maas, J.,
    8. Pien, C. S.,
    9. Prakash, S. and
    10. Elliott, P. J.
    (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Ang, S.-L. and
    2. Rossant, J.
    (1994). HNF-3 beta is essential for node and notochord formation in mouse development. Cell 78, 561-574. doi:10.1016/0092-8674(94)90522-3
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Ang, S. L.,
    2. Wierda, A.,
    3. Wong, D.,
    4. Stevens, K. A.,
    5. Cascio, S.,
    6. Rossant, J. and
    7. Zaret, K. S.
    (1993). The formation and maintenance of the definitive endoderm lineage in the mouse: involvement of HNF3/forkhead proteins. Development 119, 1301-1315.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Ao, W.,
    2. Gaudet, J.,
    3. Kent, W. J.,
    4. Muttumu, S. and
    5. Mango, S. E.
    (2004). Environmentally induced foregut remodeling by PHA-4/FoxA and DAF-12/NHR. Science 305, 1743-1746. doi:10.1126/science.1102216
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Aoki, R.,
    2. Shoshkes-Carmel, M.,
    3. Gao, N.,
    4. Shin, S.,
    5. May, C. L.,
    6. Golson, M. L.,
    7. Zahm, A. M.,
    8. Ray, M.,
    9. Wiser, C. L.,
    10. Wright, C. V. E. et al.
    (2016). Foxl1-expressing mesenchymal cells constitute the intestinal stem cell niche. Cell. Mol. Gastroenterol. Hepatol. 2, 175-188. doi:10.1016/j.jcmgh.2015.12.004
    OpenUrlCrossRefPubMed
  7. ↵
    1. Armoni, M.,
    2. Harel, C.,
    3. Karni, S.,
    4. Chen, H.,
    5. Bar-Yoseph, F.,
    6. Ver, M. R.,
    7. Quon, M. J. and
    8. Karnieli, E.
    (2006). FOXO1 represses peroxisome proliferator-activated receptor-Gamma1 and -Gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J. Biol. Chem. 281, 19881-19891. doi:10.1074/jbc.M600320200
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Bacon, C. and
    2. Rappold, G. A.
    (2012). The distinct and overlapping phenotypic spectra of FOXP1 and FOXP2 in cognitive disorders. Hum. Genet. 131, 1687-1698. doi:10.1007/s00439-012-1193-z
    OpenUrlCrossRefPubMed
  9. ↵
    1. Bacon, C.,
    2. Schneider, M.,
    3. Le Magueresse, C.,
    4. Froehlich, H.,
    5. Sticht, C.,
    6. Gluch, C.,
    7. Monyer, H. and
    8. Rappold, G. A.
    (2015). Brain-specific Foxp1 deletion impairs neuronal development and causes autistic-like behaviour. Mol. Psychiatry 20, 632-639. doi:10.1038/mp.2014.116
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bastie, C. C.,
    2. Nahle, Z.,
    3. McLoughlin, T.,
    4. Esser, K.,
    5. Zhang, W.,
    6. Unterman, T. and
    7. Abumrad, N. A.
    (2005). FoxO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and -independent mechanisms. J. Biol. Chem. 280, 14222-14229. doi:10.1074/jbc.M413625200
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Behr, R.,
    2. Brestelli, J.,
    3. Fulmer, J. T.,
    4. Miyawaki, N.,
    5. Kleyman, T. R. and
    6. Kaestner, K. H.
    (2004). Mild nephrogenic diabetes insipidus caused by Foxa1 deficiency. J. Biol. Chem. 279, 41936-41941. doi:10.1074/jbc.M403354200
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Besnard, V.,
    2. Wert, S. E.,
    3. Hull, W. M. and
    4. Whitsett, J. A.
    (2004). Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues. Gene Expr. Patterns 5, 193-208. doi:10.1016/j.modgep.2004.08.006
    OpenUrlCrossRefPubMed
  13. ↵
    1. Bodkin, N. L.,
    2. Alexander, T. M.,
    3. Ortmeyer, H. K.,
    4. Johnson, E. and
    5. Hansen, B. C.
    (2003). Mortality and morbidity in laboratory-maintained rhesus monkeys and effects of long-term dietary restriction. J. Gerontol. A Biol. Sci. Med. Sci. 58, B212-B219. doi:10.1093/gerona/58.3.B212
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Bolte, C.,
    2. Zhang, Y.,
    3. Wang, I.-C.,
    4. Kalin, T. V.,
    5. Molkentin, J. D. and
    6. Kalinichenko, V. V.
    (2011). Expression of Foxm1 transcription factor in cardiomyocytes is required for myocardial development. PLoS ONE 6, e22217. doi:10.1371/journal.pone.0022217
    OpenUrlCrossRefPubMed
  15. ↵
    1. Bowers, J. M. and
    2. Konopka, G.
    (2012). The role of the FOXP family of transcription factors in ASD. Dis. Markers 33, 251-260. doi:10.1155/2012/456787
    OpenUrlCrossRefPubMed
  16. ↵
    1. Bramswig, N. C.,
    2. Everett, L. J.,
    3. Schug, J.,
    4. Dorrell, C.,
    5. Liu, C.,
    6. Luo, Y.,
    7. Streeter, P. R.,
    8. Naji, A.,
    9. Grompe, M. and
    10. Kaestner, K. H.
    (2013). Epigenomic plasticity enables human pancreatic alpha to beta cell reprogramming. J. Clin. Invest. 123, 1275-1284. doi:10.1172/JCI66514
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Brezillon, N.,
    2. Lambert-Blot, M.,
    3. Morosan, S.,
    4. Couton, D.,
    5. Mitchell, C.,
    6. Kremsdorf, D.,
    7. Costa, R. H.,
    8. Gilgenkrantz, H. and
    9. Guidotti, J.-E.
    (2007). Transplanted hepatocytes over-expressing FoxM1B efficiently repopulate chronically injured mouse liver independent of donor age. Mol. Ther. 15, 1710-1715. doi:10.1038/sj.mt.6300232
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Byrne, A. B.,
    2. Walradt, T.,
    3. Gardner, K. E.,
    4. Hubbert, A.,
    5. Reinke, V. and
    6. Hammarlund, M.
    (2014). Insulin/IGF1 signaling inhibits age-dependent axon regeneration. Neuron 81, 561-573. doi:10.1016/j.neuron.2013.11.019
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Caravaca, J. M.,
    2. Donahue, G.,
    3. Becker, J. S.,
    4. He, X.,
    5. Vinson, C. and
    6. Zaret, K. S.
    (2013). Bookmarking by specific and nonspecific binding of Foxa1 pioneer factor to mitotic chromosomes. Genes Dev. 27, 251-260. doi:10.1101/gad.206458.112
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Carroll, J. S.,
    2. Liu, X. S.,
    3. Brodsky, A. S.,
    4. Li, W.,
    5. Meyer, C. A.,
    6. Szary, A. J.,
    7. Eeckhoute, J.,
    8. Shao, W.,
    9. Hestermann, E. V.,
    10. Geistlinger, T. R. et al.
    (2005). Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43. doi:10.1016/j.cell.2005.05.008
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Chen, X.,
    2. Muller, G. A.,
    3. Quaas, M.,
    4. Fischer, M.,
    5. Han, N.,
    6. Stutchbury, B.,
    7. Sharrocks, A. D. and
    8. Engeland, K.
    (2013). The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol. Cell. Biol. 33, 227-236. doi:10.1128/MCB.00881-12
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Cirillo, L. A.,
    2. Lin, F. R.,
    3. Cuesta, I.,
    4. Friedman, D.,
    5. Jarnik, M. and
    6. Zaret, K. S.
    (2002). Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and Gata-4. Mol. Cell 9, 279-289. doi:10.1016/S1097-2765(02)00459-8
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Clark, K. L.,
    2. Halay, E. D.,
    3. Lai, E. and
    4. Burley, S. K.
    (1993). Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364, 412-420. doi:10.1038/364412a0
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Colman, R. J.,
    2. Anderson, R. M.,
    3. Johnson, S. C.,
    4. Kastman, E. K.,
    5. Kosmatka, K. J.,
    6. Beasley, T. M.,
    7. Allison, D. B.,
    8. Cruzen, C.,
    9. Simmons, H. A.,
    10. Kemnitz, J. W. et al.
    (2009). Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325, 201-204. doi:10.1126/science.1173635
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Costa, R. H.,
    2. Grayson, D. R. and
    3. Darnell, J. E. Jr.
    . (1989). Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol. Cell. Biol. 9, 1415-1425. doi:10.1128/MCB.9.4.1415
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Cuesta, I.,
    2. Zaret, K. S. and
    3. Santisteban, P.
    (2007). The forkhead factor FoxE1 binds to the thyroperoxidase promoter during thyroid cell differentiation and modifies compacted chromatin structure. Mol. Cell. Biol. 27, 7302-7314. doi:10.1128/MCB.00758-07
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. DeGraff, D. J.,
    2. Grabowska, M. M.,
    3. Case, T. C.,
    4. Yu, X.,
    5. Herrick, M. K.,
    6. Hayward, W. J.,
    7. Strand, D. W.,
    8. Cates, J. M.,
    9. Hayward, S. W.,
    10. Gao, N. et al.
    (2014). FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype. Lab. Invest. 94, 726-739. doi:10.1038/labinvest.2014.64
    OpenUrlCrossRefPubMed
  28. ↵
    1. Fielenbach, N. and
    2. Antebi, A.
    (2008). C. elegans Dauer formation and the molecular basis of plasticity. Genes Dev. 22, 2149-2165. doi:10.1101/gad.1701508
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Flachsbart, F.,
    2. Caliebe, A.,
    3. Kleindorp, R.,
    4. Blanche, H.,
    5. von Eller-Eberstein, H.,
    6. Nikolaus, S.,
    7. Schreiber, S. and
    8. Nebel, A.
    (2009). Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc. Natl. Acad. Sci. USA 106, 2700-2705. doi:10.1073/pnas.0809594106
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Fontenot, J. D.,
    2. Gavin, M. A. and
    3. Rudensky, A. Y.
    (2003). Foxp3 programs the development and function of Cd4+Cd25+ regulatory T cells. Nat. Immunol. 4, 330-336. doi:10.1038/ni904
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Friedman, J. R. and
    2. Kaestner, K. H.
    (2006). The Foxa family of transcription factors in development and metabolism. Cell. Mol. Life Sci. 63, 2317-2328. doi:10.1007/s00018-006-6095-6
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Gao, N.,
    2. Zhang, J.,
    3. Rao, M. A.,
    4. Case, T. C.,
    5. Mirosevich, J.,
    6. Wang, Y.,
    7. Jin, R.,
    8. Gupta, A.,
    9. Rennie, P. S. and
    10. Matusik, R. J.
    (2003). The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 17, 1484-1507. doi:10.1210/me.2003-0020
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Gao, N.,
    2. Ishii, K.,
    3. Mirosevich, J.,
    4. Kuwajima, S.,
    5. Oppenheimer, S. R.,
    6. Roberts, R. L.,
    7. Jiang, M.,
    8. Yu, X.,
    9. Shappell, S. B.,
    10. Caprioli, R. M. et al.
    (2005). Forkhead Box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132, 3431-3443. doi:10.1242/dev.01917
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Gao, N.,
    2. LeLay, J.,
    3. Vatamaniuk, M. Z.,
    4. Rieck, S.,
    5. Friedman, J. R. and
    6. Kaestner, K. H.
    (2008). Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev. 22, 3435-3448. doi:10.1101/gad.1752608
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Gartel, A. L.
    (2010). A new target for proteasome inhibitors: Foxm1. Expert Opin. Investig. Drugs 19, 235-242. doi:10.1517/13543780903563364
    OpenUrlCrossRefPubMed
  36. ↵
    1. Gaudet, J. and
    2. Mango, S. E.
    (2002). Regulation of organogenesis by the Caenorhabditis elegans Foxa protein PHA-4. Science 295, 821-825. doi:10.1126/science.1065175
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Golson, M. L.,
    2. Misfeldt, A. A.,
    3. Kopsombut, U. G.,
    4. Petersen, C. P. and
    5. Gannon, M.
    (2010). High fat diet regulation of beta-cell proliferation and beta-cell mass. Open Endocrinol. J. 4, 66-77. doi:10.2174/1874216501004010066
    OpenUrlCrossRef
  38. ↵
    1. Golson, M. L.,
    2. Dunn, J. C.,
    3. Maulis, M. F.,
    4. Dadi, P. K.,
    5. Osipovich, A. B.,
    6. Magnuson, M. A.,
    7. Jacobson, D. A. and
    8. Gannon, M.
    (2015). Activation of FoxM1 revitalizes the replicative potential of aged beta-cells in male mice and enhances insulin secretion. Diabetes 64, 3829-3838. doi:10.2337/db15-0465
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Gormally, M. V.,
    2. Dexheimer, T. S.,
    3. Marsico, G.,
    4. Sanders, D. A.,
    5. Lowe, C.,
    6. Matak-Vinković, D.,
    7. Michael, S.,
    8. Jadhav, A.,
    9. Rai, G.,
    10. Maloney, D. J. et al.
    (2014). Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat. Commun. 5, 5165. doi:10.1038/ncomms6165
    OpenUrlCrossRefPubMed
  40. ↵
    1. Gross, D. N.,
    2. van den Heuvel, A. P. J. and
    3. Birnbaum, M. J.
    (2008). The role of FoxO in the regulation of metabolism. Oncogene 27, 2320-2336. doi:10.1038/onc.2008.25
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Gusarova, G. A.,
    2. Wang, I.-C.,
    3. Major, M. L.,
    4. Kalinichenko, V. V.,
    5. Ackerson, T.,
    6. Petrovic, V. and
    7. Costa, R. H.
    (2007). A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest. 117, 99-111. doi:10.1172/JCI27527
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Habashy, H. O.,
    2. Powe, D. G.,
    3. Rakha, E. A.,
    4. Ball, G.,
    5. Paish, C.,
    6. Gee, J.,
    7. Nicholson, R. I. and
    8. Ellis, I. O.
    (2008). Forkhead-box A1 (Foxa1) expression in breast cancer and its prognostic significance. Eur. J. Cancer 44, 1541-1551. doi:10.1016/j.ejca.2008.04.020
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. Haesler, S.,
    2. Rochefort, C.,
    3. Georgi, B.,
    4. Licznerski, P.,
    5. Osten, P. and
    6. Scharff, C.
    (2007). Incomplete and inaccurate vocal imitation after knockdown of Foxp2 in songbird basal ganglia nucleus area X. PLoS Biol. 5, e321. doi:10.1371/journal.pbio.0050321
    OpenUrlCrossRefPubMed
  44. ↵
    1. Haeusler, R. A.,
    2. Kaestner, K. H. and
    3. Accili, D.
    (2010). FoxOs function synergistically to promote glucose production. J. Biol. Chem. 285, 35245-35248. doi:10.1074/jbc.C110.175851
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Halasi, M. and
    2. Gartel, A. L.
    (2012). Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS ONE 7, e31761. doi:10.1371/journal.pone.0031761
    OpenUrlCrossRefPubMed
  46. ↵
    1. Halasi, M. and
    2. Gartel, A. L.
    (2013). FOX(M1) news--it is cancer. Mol. Cancer Ther. 12, 245-254. doi:10.1158/1535-7163.MCT-12-0712
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Halasi, M.,
    2. Pandit, B.,
    3. Wang, M.,
    4. Nogueira, V.,
    5. Hay, N. and
    6. Gartel, A. L.
    (2013). Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits Xenograft tumor growth. Am. J. Pathol. 183, 257-265. doi:10.1016/j.ajpath.2013.03.012
    OpenUrlCrossRef
  48. ↵
    1. Halmos, B.,
    2. Basseres, D. S.,
    3. Monti, S.,
    4. D'alo, F.,
    5. Dayaram, T.,
    6. Ferenczi, K.,
    7. Wouters, B. J.,
    8. Huettner, C. S.,
    9. Golub, T. R. and
    10. Tenen, D. G.
    (2004). A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer Res. 64, 4137-4147. doi:10.1158/0008-5472.CAN-03-4052
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Hamdan, F. F.,
    2. Daoud, H.,
    3. Rochefort, D.,
    4. Piton, A.,
    5. Gauthier, J.,
    6. Langlois, M.,
    7. Foomani, G.,
    8. Dobrzeniecka, S.,
    9. Krebs, M.-O.,
    10. Joober, R. et al.
    (2010). De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. Am. J. Hum. Genet. 87, 671-678. doi:10.1016/j.ajhg.2010.09.017
    OpenUrlCrossRefPubMed
  50. ↵
    1. Hannenhalli, S. and
    2. Kaestner, K. H.
    (2009). The evolution of Fox genes and their role in development and disease. Nat. Rev. Genet. 10, 233-240. doi:10.1038/nrg2523
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    1. Hatta, M. and
    2. Cirillo, L. A.
    (2007). Chromatin opening and stable perturbation of core histone:DNA contacts by FoxO1. J. Biol. Chem. 282, 35583-35593. doi:10.1074/jbc.M704735200
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Heilbronn, L. K. and
    2. Ravussin, E.
    (2003). Calorie restriction and aging: review of the literature and implications for studies in humans. Am. J. Clin. Nutr. 78, 361-369.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Horn, D.,
    2. Kapeller, J.,
    3. Rivera-Brugués, N.,
    4. Moog, U.,
    5. Lorenz-Depiereux, B.,
    6. Eck, S.,
    7. Hempel, M.,
    8. Wagenstaller, J.,
    9. Gawthrope, A.,
    10. Monaco, A. P. et al.
    (2010). Identification of FOXP1 deletions in three unrelated patients with mental retardation and significant speech and language deficits. Hum. Mutat. 31, E1851-E1860. doi:10.1002/humu.21362
    OpenUrlCrossRefPubMed
  54. ↵
    1. Hsu, H.-T.,
    2. Chen, H.-M.,
    3. Yang, Z.,
    4. Wang, J.,
    5. Lee, N. K.,
    6. Burger, A.,
    7. Zaret, K.,
    8. Liu, T.,
    9. Levine, E. and
    10. Mango, S. E.
    (2015). Recruitment of RNA polymerase II by the pioneer transcription factor PHA-4. Science 348, 1372-1376. doi:10.1126/science.aab1223
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Hurtado, A.,
    2. Holmes, K. A.,
    3. Ross-Innes, C. S.,
    4. Schmidt, D. and
    5. Carroll, J. S.
    (2011). FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27-33. doi:10.1038/ng.730
    OpenUrlCrossRefPubMed
  56. ↵
    1. Imamura, Y.,
    2. Sakamoto, S.,
    3. Endo, T.,
    4. Utsumi, T.,
    5. Fuse, M.,
    6. Suyama, T.,
    7. Kawamura, K.,
    8. Imamoto, T.,
    9. Yano, K.,
    10. Uzawa, K. et al.
    (2012). FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. PLoS ONE 7, e42456. doi:10.1371/journal.pone.0042456
    OpenUrlCrossRefPubMed
  57. ↵
    1. Iwafuchi-Doi, M. and
    2. Zaret, K. S.
    (2016). Cell fate control by pioneer transcription factors. Development 143, 1833-1837. doi:10.1242/dev.133900
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Iwafuchi-Doi, M.,
    2. Donahue, G.,
    3. Kakumanu, A.,
    4. Watts, J. A.,
    5. Mahony, S.,
    6. Pugh, B. F.,
    7. Lee, D.,
    8. Kaestner, K. H. and
    9. Zaret, K. S.
    (2016). The pioneer transcription factor FoxA maintains an accessible nucleosome configuration at enhancers for tissue-specific gene activation. Mol. Cell 62, 79-91. doi:10.1016/j.molcel.2016.03.001
    OpenUrlCrossRefPubMed
  59. ↵
    1. Jepsen, K.,
    2. Gleiberman, A. S.,
    3. Shi, C.,
    4. Simon, D. I. and
    5. Rosenfeld, M. G.
    (2008). Cooperative regulation in development by SMRT and FOXP1. Genes Dev. 22, 740-745. doi:10.1101/gad.1637108
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Jones, D.,
    2. Wade, M.,
    3. Nakjang, S.,
    4. Chaytor, L.,
    5. Grey, J.,
    6. Robson, C. N. and
    7. Gaughan, L.
    (2015). FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget 6, 29782-29794. doi:10.18632/oncotarget.4927
    OpenUrlCrossRef
  61. ↵
    1. Kaestner, K. H.,
    2. Hiemisch, H.,
    3. Luckow, B. and
    4. Schütz, G.
    (1994). The HNF-3 gene family of transcription factors in mice: gene structure, cDNA sequence, and mRNA distribution. Genomics 20, 377-385. doi:10.1006/geno.1994.1191
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    1. Kaestner, K. H.,
    2. Katz, J.,
    3. Liu, Y.,
    4. Drucker, D. J. and
    5. Schutz, G.
    (1999). Inactivation of the winged helix transcription factor HNF3ALPHA affects glucose homeostasis and islet glucagon gene expression in vivo. Genes Dev. 13, 495-504. doi:10.1101/gad.13.4.495
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Kaletsky, R.,
    2. Lakhina, V.,
    3. Arey, R.,
    4. Williams, A.,
    5. Landis, J.,
    6. Ashraf, J. and
    7. Murphy, C. T.
    (2016). The C. elegans adult neuronal IIS/FOXO transcriptome reveals adult phenotype regulators. Nature 529, 92-96. doi:10.1038/nature16483
    OpenUrlCrossRefPubMed
  64. ↵
    1. Kalin, T. V.,
    2. Wang, I.-C.,
    3. Meliton, L.,
    4. Zhang, Y.,
    5. Wert, S. E.,
    6. Ren, X.,
    7. Snyder, J.,
    8. Bell, S. M.,
    9. Graf, L., Jr.,
    10. Whitsett, J. A. et al.
    (2008). Forkhead Box M1 transcription factor is required for perinatal lung function. Proc. Natl. Acad. Sci. USA 105, 19330-19335. doi:10.1073/pnas.0806748105
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Kalinichenko, V. V.,
    2. Gusarova, G. A.,
    3. Tan, Y.,
    4. Wang, I.-C.,
    5. Major, M. L.,
    6. Wang, X.,
    7. Yoder, H. M. and
    8. Costal, R. H.
    (2003). Ubiquitous expression of the Forkhead Box M1b transgene accelerates proliferation of distinct pulmonary cell types following lung injury. J. Biol. Chem. 278, 37888-37894. doi:10.1074/jbc.M305555200
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Kalinina, O. A.,
    2. Kalinin, S. A.,
    3. Polack, E. W.,
    4. Mikaelian, I.,
    5. Panda, S.,
    6. Costa, R. H. and
    7. Adami, G. R.
    (2003). Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions. Oncogene 22, 6266-6276. doi:10.1038/sj.onc.1206640
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Kauffman, A. L.,
    2. Ashraf, J. M.,
    3. Corces-Zimmerman, M. R.,
    4. Landis, J. N. and
    5. Murphy, C. T.
    (2010). Insulin signaling and dietary restriction differentially influence the decline of learning and memory with age. PLoS Biol. 8, e1000372. doi:10.1371/journal.pbio.1000372
    OpenUrlCrossRefPubMed
  68. ↵
    1. Kitamura, Y. I.,
    2. Kitamura, T.,
    3. Kruse, J.-P.,
    4. Raum, J. C.,
    5. Stein, R.,
    6. Gu, W. and
    7. Accili, D.
    (2005). Foxo1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab. 2, 153-163. doi:10.1016/j.cmet.2005.08.004
    OpenUrlCrossRefPubMedWeb of Science
  69. ↵
    1. Kittappa, R.,
    2. Chang, W. W.,
    3. Awatramani, R. B. and
    4. McKay, R. D. G.
    (2007). The Foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. PLoS Biol. 5, e325. doi:10.1371/journal.pbio.0050325
    OpenUrlCrossRefPubMed
  70. ↵
    1. Kobayashi, M.,
    2. Kikuchi, O.,
    3. Sasaki, T.,
    4. Kim, H.-J.,
    5. Yokota-Hashimoto, H.,
    6. Lee, Y.-S.,
    7. Amano, K.,
    8. Kitazumi, T.,
    9. Susanti, V. Y.,
    10. Kitamura, Y. I. et al.
    (2012). FoxO1 as a double-edged sword in the pancreas: analysis of pancreas- and beta-cell-specific Foxo1 knockout mice. Am. J. Physiol. Endocrinol. Metab. 302, E603-E613. doi:10.1152/ajpendo.00469.2011
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Kojima, T.,
    2. Kamei, H.,
    3. Aizu, T.,
    4. Arai, Y.,
    5. Takayama, M.,
    6. Nakazawa, S.,
    7. Ebihara, Y.,
    8. Inagaki, H.,
    9. Masui, Y.,
    10. Gondo, Y. et al.
    (2004). Association analysis between longevity in the Japanese population and polymorphic variants of genes involved in insulin and insulin-like growth factor 1 signaling pathways. Exp. Gerontol. 39, 1595-1598. doi:10.1016/j.exger.2004.05.007
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    1. Kops, G. J. P. L.,
    2. Dansen, T. B.,
    3. Polderman, P. E.,
    4. Saarloos, I.,
    5. Wirtz, K. W. A.,
    6. Coffer, P. J.,
    7. Huang, T.-T.,
    8. Bos, J. L.,
    9. Medema, R. H. and
    10. Burgering, B. M. T.
    (2002). Forkhead transcription factor Foxo3a protects quiescent cells from oxidative stress. Nature 419, 316-321. doi:10.1038/nature01036
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    1. Korver, W.,
    2. Roose, J. and
    3. Clevers, H.
    (1997). The winged-helix transcription factor trident is expressed in cycling cells. Nucleic Acids Res. 25, 1715-1719. doi:10.1093/nar/25.9.1715
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Krupczak-Hollis, K.,
    2. Wang, X.,
    3. Kalinichenko, V. V.,
    4. Gusarova, G. A.,
    5. Wang, I.-C.,
    6. Dennewitz, M. B.,
    7. Yoder, H. M.,
    8. Kiyokawa, H.,
    9. Kaestner, K. H. and
    10. Costa, R. H.
    (2004). The mouse Forkhead Box M1 transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. Dev. Biol. 276, 74-88. doi:10.1016/j.ydbio.2004.08.022
    OpenUrlCrossRefPubMedWeb of Science
  75. ↵
    1. Lai, C. S. L.,
    2. Fisher, S. E.,
    3. Hurst, J. A.,
    4. Vargha-Khadem, F. and
    5. Monaco, A. P.
    (2001). A Forkhead-domain gene is mutated in a severe speech and language disorder. Nature 413, 519-523. doi:10.1038/35097076
    OpenUrlCrossRefPubMedWeb of Science
  76. ↵
    1. Lal, G. and
    2. Bromberg, J. S.
    (2009). Epigenetic mechanisms of regulation of Foxp3 expression. Blood 114, 3727-3735. doi:10.1182/blood-2009-05-219584
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Lantz, K. A.,
    2. Vatamaniuk, M. Z.,
    3. Brestelli, J. E.,
    4. Friedman, J. R.,
    5. Matschinsky, F. M. and
    6. Kaestner, K. H.
    (2004). Foxa2 regulates multiple pathways of insulin secretion. J. Clin. Invest. 114, 512-520. doi:10.1172/JCI21149
    OpenUrlCrossRefPubMedWeb of Science
  78. ↵
    1. Laoukili, J.,
    2. Stahl, M. and
    3. Medema, R. H.
    (2007). Foxm1: at the crossroads of ageing and cancer. Biochim. Biophys. Acta 1775, 92-102. doi:10.1016/j.bbcan.2006.08.006
    OpenUrlCrossRefPubMed
  79. ↵
    1. Lee, C. S.,
    2. Friedman, J. R.,
    3. Fulmer, J. T. and
    4. Kaestner, K. H.
    (2005a). The initiation of liver development is dependent on Foxa transcription factors. Nature 435, 944-947. doi:10.1038/nature03649
    OpenUrlCrossRefPubMedWeb of Science
  80. ↵
    1. Lee, C. S.,
    2. Sund, N. J.,
    3. Behr, R.,
    4. Herrera, P. L. and
    5. Kaestner, K. H.
    (2005b). Foxa2 is required for the differentiation of pancreatic alpha-cells. Dev. Biol. 278, 484-495. doi:10.1016/j.ydbio.2004.10.012
    OpenUrlCrossRefPubMedWeb of Science
  81. ↵
    1. Li, S.,
    2. Weidenfeld, J. and
    3. Morrisey, E. E.
    (2004a). Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol. Cell. Biol. 24, 809-822. doi:10.1128/MCB.24.2.809-822.2004
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Li, S.,
    2. Zhou, D.,
    3. Lu, M. M. and
    4. Morrisey, E. E.
    (2004b). Advanced cardiac morphogenesis does not require heart tube fusion. Science 305, 1619-1622. doi:10.1126/science.1098674
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Li, B.,
    2. Samanta, A.,
    3. Song, X.,
    4. Iacono, K. T.,
    5. Bembas, K.,
    6. Tao, R.,
    7. Basu, S.,
    8. Riley, J. L.,
    9. Hancock, W. W.,
    10. Shen, Y. et al.
    (2007). Foxp3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl. Acad. Sci. USA 104, 4571-4576. doi:10.1073/pnas.0700298104
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Li, Y.,
    2. Wang, W.-J.,
    3. Cao, H.,
    4. Lu, J.,
    5. Wu, C.,
    6. Hu, F.-Y.,
    7. Guo, J.,
    8. Zhao, L.,
    9. Yang, F.,
    10. Zhang, Y.-X. et al.
    (2009). Genetic association of Foxo1a and Foxo3a with longevity trait in Han Chinese populations. Hum. Mol. Genet. 18, 4897-4904. doi:10.1093/hmg/ddp459
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. Li, Z.,
    2. Schug, J.,
    3. Tuteja, G.,
    4. White, P. and
    5. Kaestner, K. H.
    (2011). The nucleosome map of the mammalian liver. Nat. Struct. Mol. Biol. 18, 742-746. doi:10.1038/nsmb.2060
    OpenUrlCrossRefPubMed
  86. ↵
    1. Li, S.,
    2. Wang, Y.,
    3. Zhang, Y.,
    4. Lu, M. M.,
    5. DeMayo, F. J.,
    6. Dekker, J. D.,
    7. Tucker, P. W. and
    8. Morrisey, E. E.
    (2012a). Foxp1/4 control epithelial cell fate during lung development and regeneration through regulation of anterior gradient 2. Development 139, 2500-2509. doi:10.1242/dev.079699
    OpenUrlAbstract/FREE Full Text
  87. ↵
    1. Li, Z.,
    2. Gadue, P.,
    3. Chen, K.,
    4. Jiao, Y.,
    5. Tuteja, G.,
    6. Schug, J.,
    7. Li, W. and
    8. Kaestner, K. H.
    (2012b). Foxa2 and H2a.Z mediate nucleosome depletion during embryonic stem cell differentiation. Cell 151, 1608-1616. doi:10.1016/j.cell.2012.11.018
    OpenUrlCrossRefPubMedWeb of Science
  88. ↵
    1. Li, Z.,
    2. Tuteja, G.,
    3. Schug, J. and
    4. Kaestner, K. H.
    (2012c). Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 148, 72-83. doi:10.1016/j.cell.2011.11.026
    OpenUrlCrossRefPubMedWeb of Science
  89. ↵
    1. Li, C. M.-C.,
    2. Gocheva, V.,
    3. Oudin, M. J.,
    4. Bhutkar, A.,
    5. Wang, S. Y.,
    6. Date, S. R.,
    7. Ng, S. R.,
    8. Whittaker, C. A.,
    9. Bronson, R. T.,
    10. Snyder, E. L. et al.
    (2015a). Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev. 29, 1850-1862. doi:10.1101/gad.267393.115
    OpenUrlAbstract/FREE Full Text
  90. ↵
    1. Li, X.,
    2. Wang, W.,
    3. Wang, J.,
    4. Malovannaya, A.,
    5. Xi, Y.,
    6. Li, W.,
    7. Guerra, R.,
    8. Hawke, D. H.,
    9. Qin, J. and
    10. Chen, J.
    (2015b). Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes. Mol. Syst. Biol. 11, 775. doi:10.15252/msb.20145504
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. Liao, C.-Y.,
    2. Rikke, B. A.,
    3. Johnson, T. E.,
    4. Diaz, V. and
    5. Nelson, J. F.
    (2010). Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. Aging Cell 9, 92-95. doi:10.1111/j.1474-9726.2009.00533.x
    OpenUrlCrossRefPubMedWeb of Science
  92. ↵
    1. Libina, N.,
    2. Berman, J. R. and
    3. Kenyon, C.
    (2003). Tissue-specific activities of C. elegans Daf-16 in the regulation of lifespan. Cell 115, 489-502. doi:10.1016/S0092-8674(03)00889-4
    OpenUrlCrossRefPubMedWeb of Science
  93. ↵
    1. Littler, D. R.,
    2. Alvarez-Fernandez, M.,
    3. Stein, A.,
    4. Hibbert, R. G.,
    5. Heidebrecht, T.,
    6. Aloy, P.,
    7. Medema, R. H. and
    8. Perrakis, A.
    (2010). Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence. Nucleic Acids Res. 38, 4527-4538. doi:10.1093/nar/gkq194
    OpenUrlAbstract/FREE Full Text
  94. ↵
    1. Lupien, M.,
    2. Eeckhoute, J.,
    3. Meyer, C. A.,
    4. Wang, Q.,
    5. Zhang, Y.,
    6. Li, W.,
    7. Carroll, J. S.,
    8. Liu, X. S. and
    9. Brown, M.
    (2008). FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970. doi:10.1016/j.cell.2008.01.018
    OpenUrlCrossRefPubMedWeb of Science
  95. ↵
    1. Martins, R.,
    2. Lithgow, G. J. and
    3. Link, W.
    (2015). Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell 15, 196-207. doi:10.1111/acel.12427
    OpenUrlCrossRef
  96. ↵
    1. Matsumoto, M.,
    2. Pocai, A.,
    3. Rossetti, L.,
    4. DePinho, R. A. and
    5. Accili, D.
    (2007). Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 6, 208-216. doi:10.1016/j.cmet.2007.08.006
    OpenUrlCrossRefPubMedWeb of Science
  97. ↵
    1. Mattison, J. A.,
    2. Roth, G. S.,
    3. Beasley, T. M.,
    4. Tilmont, E. M.,
    5. Handy, A. M.,
    6. Herbert, R. L.,
    7. Longo, D. L.,
    8. Allison, D. B.,
    9. Young, J. E.,
    10. Bryant, M. et al.
    (2012). Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489, 318-321. doi:10.1038/nature11432
    OpenUrlCrossRefPubMedWeb of Science
  98. ↵
    1. Mercer, F. and
    2. Unutmaz, D.
    (2009). The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. Adv. Exp. Med. Biol. 665, 47-59. doi:10.1007/978-1-4419-1599-3_4
    OpenUrlCrossRefPubMed
  99. ↵
    1. Monaghan, A. P.,
    2. Kaestner, K. H.,
    3. Grau, E. and
    4. Schutz, G.
    (1993). Postimplantation expression patterns indicate a role for the mouse forkhead/HNF-3 alpha, beta and gamma genes in determination of the definitive endoderm, chordamesoderm and neuroectoderm. Development 119, 567-578.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Mulvey, L.,
    2. Sinclair, A. and
    3. Selman, C.
    (2014). Lifespan modulation in mice and the confounding effects of genetic background. J. Genet. Genomics 41, 497-503. doi:10.1016/j.jgg.2014.06.002
    OpenUrlCrossRefPubMed
  101. ↵
    1. Murakami, H.,
    2. Bessinger, K.,
    3. Hellmann, J. and
    4. Murakami, S.
    (2005). Aging-dependent and -independent modulation of associative learning behavior by insulin/insulin-like growth factor-1 signal in Caenorhabditis elegans. J. Neurosci. 25, 10894-10904. doi:10.1523/JNEUROSCI.3600-04.2005
    OpenUrlAbstract/FREE Full Text
  102. ↵
    1. Murphy, C. T.,
    2. Lee, S.-J. and
    3. Kenyon, C.
    (2007). Tissue entrainment by feedback regulation of insulin gene expression in the endoderm of Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 104, 19046-19050. doi:10.1073/pnas.0709613104
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Nagy, S.,
    2. Tramm, N.,
    3. Sanders, J.,
    4. Iwanir, S.,
    5. Shirley, I. A.,
    6. Levine, E. and
    7. Biron, D.
    (2014). Homeostasis in C. elegans sleep is characterized by two behaviorally and genetically distinct mechanisms. Elife 3, e04380. doi:10.7554/eLife.04380
    OpenUrlAbstract/FREE Full Text
  104. ↵
    1. Nakae, J.,
    2. Biggs, W. H., III.,
    3. Kitamura, T.,
    4. Cavenee, W. K.,
    5. Wright, C. V. E.,
    6. Arden, K. C. and
    7. Accili, D.
    (2002). Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat. Genet. 32, 245-253. doi:10.1038/ng890
    OpenUrlCrossRefPubMedWeb of Science
  105. ↵
    1. Nemoto, S. and
    2. Finkel, T.
    (2002). Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295, 2450-2452. doi:10.1126/science.1069004
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Okamoto, H.,
    2. Hribal, M. L.,
    3. Lin, H. V.,
    4. Bennett, W. R.,
    5. Ward, A. and
    6. Accili, D.
    (2006). Role of the forkhead protein Foxo1 in beta cell compensation to insulin resistance. J. Clin. Invest. 116, 775-782. doi:10.1172/JCI24967
    OpenUrlCrossRefPubMedWeb of Science
  107. ↵
    1. Panowski, S. H.,
    2. Wolff, S.,
    3. Aguilaniu, H.,
    4. Durieux, J. and
    5. Dillin, A.
    (2007). PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature 447, 550-555. doi:10.1038/nature05837
    OpenUrlCrossRefPubMedWeb of Science
  108. ↵
    1. Pawlikowska, L.,
    2. Hu, D.,
    3. Huntsman, S.,
    4. Sung, A.,
    5. Chu, C.,
    6. Chen, J.,
    7. Joyner, A. H.,
    8. Schork, N. J.,
    9. Hsueh, W.-C.,
    10. Reiner, A. P. et al.
    (2009). Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell 8, 460-472. doi:10.1111/j.1474-9726.2009.00493.x
    OpenUrlCrossRefPubMedWeb of Science
  109. ↵
    1. Pohl, B. S. and
    2. Knöchel, W.
    (2005). Of Fox and frogs: Fox (fork head/winged helix) transcription factors in Xenopus development. Gene 344, 21-32. doi:10.1016/j.gene.2004.09.037
    OpenUrlCrossRefPubMed
  110. ↵
    1. Ren, H.,
    2. Zhang, P.,
    3. Tang, Y.,
    4. Wu, M. and
    5. Zhang, W.
    (2015). Forkhead box protein A1 is a prognostic predictor and promotes tumor growth of gastric cancer. Onco Targets Ther. 8, 3029-3039. doi:10.2147/OTT.S91035
    OpenUrlCrossRef
  111. ↵
    1. Riedel, C. G.,
    2. Dowen, R. H.,
    3. Lourenco, G. F.,
    4. Kirienko, N. V.,
    5. Heimbucher, T.,
    6. West, J. A.,
    7. Bowman, S. K.,
    8. Kingston, R. E.,
    9. Dillin, A.,
    10. Asara, J. M. et al.
    (2013). Daf-16 employs the chromatin remodeller SWI/SNF to promote stress resistance and longevity. Nat. Cell Biol. 15, 491-501. doi:10.1038/ncb2720
    OpenUrlCrossRefPubMedWeb of Science
  112. ↵
    1. Ross-Innes, C. S.,
    2. Stark, R.,
    3. Teschendorff, A. E.,
    4. Holmes, K. A.,
    5. Ali, H. R.,
    6. Dunning, M. J.,
    7. Brown, G. D.,
    8. Gojis, O.,
    9. Ellis, I. O.,
    10. Green, A. R. et al.
    (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393. doi:10.1038/nature10730
    OpenUrlCrossRefPubMedWeb of Science
  113. ↵
    1. Sackett, S. D.,
    2. Li, Z.,
    3. Hurtt, R.,
    4. Gao, Y.,
    5. Wells, R. G.,
    6. Brondell, K.,
    7. Kaestner, K. H. and
    8. Greenbaum, L. E.
    (2009). Foxl1 is a marker of bipotential hepatic progenitor cells in mice. Hepatology 49, 920-929. doi:10.1002/hep.22705
    OpenUrlCrossRefPubMedWeb of Science
  114. ↵
    1. Sanders, D. A.,
    2. Ross-Innes, C. S.,
    3. Beraldi, D.,
    4. Carroll, J. S. and
    5. Balasubramanian, S.
    (2013). Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. Genome Biol. 14, R6. doi:10.1186/gb-2013-14-1-r6
    OpenUrlCrossRefPubMed
  115. ↵
    1. Sheaffer, K. L.,
    2. Updike, D. L. and
    3. Mango, S. E.
    (2008). The target of rapamycin pathway antagonizes PHA-4/FoxA to control development and aging. Curr. Biol. 18, 1355-1364. doi:10.1016/j.cub.2008.07.097
    OpenUrlCrossRefPubMedWeb of Science
  116. ↵
    1. Shen, W.,
    2. Scearce, L. M.,
    3. Brestelli, J. E.,
    4. Sund, N. J. and
    5. Kaestner, K. H.
    (2001). Foxa3 (hepatocyte nuclear factor 3gamma) is required for the regulation of hepatic GLUT2 expression and the maintenance of glucose homeostasis during a prolonged fast. J. Biol. Chem. 276, 42812-42817. doi:10.1074/jbc.M106344200
    OpenUrlAbstract/FREE Full Text
  117. ↵
    1. Shimokawa, I.,
    2. Komatsu, T.,
    3. Hayashi, N.,
    4. Kim, S.-E.,
    5. Kawata, T.,
    6. Park, S.,
    7. Hayashi, H.,
    8. Yamaza, H.,
    9. Chiba, T. and
    10. Mori, R.
    (2015). The life-extending effect of dietary restriction requires Foxo3 in mice. Aging Cell 14, 707-709. doi:10.1111/acel.12340
    OpenUrlCrossRef
  118. ↵
    1. Shu, W.,
    2. Yang, H.,
    3. Zhang, L.,
    4. Lu, M. M. and
    5. Morrisey, E. E.
    (2001). Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J. Biol. Chem. 276, 27488-27497. doi:10.1074/jbc.M100636200
    OpenUrlAbstract/FREE Full Text
  119. ↵
    1. Shu, W.,
    2. Cho, J. Y.,
    3. Jiang, Y.,
    4. Zhang, M.,
    5. Weisz, D.,
    6. Elder, G. A.,
    7. Schmeidler, J.,
    8. De Gasperi, R.,
    9. Sosa, M. A. G.,
    10. Rabidou, D. et al.
    (2005). Altered ultrasonic vocalization in mice with a disruption in the Foxp2 gene. Proc. Natl. Acad. Sci. USA 102, 9643-9648. doi:10.1073/pnas.0503739102
    OpenUrlAbstract/FREE Full Text
  120. ↵
    1. Silva, J. P.,
    2. von Meyenn, F.,
    3. Howell, J.,
    4. Thorens, B.,
    5. Wolfrum, C. and
    6. Stoffel, M.
    (2009). Regulation of adaptive behaviour during fasting by hypothalamic Foxa2. Nature 462, 646-650. doi:10.1038/nature08589
    OpenUrlCrossRefPubMedWeb of Science
  121. ↵
    1. Sisci, D.,
    2. Maris, P.,
    3. Cesario, M. G.,
    4. Anselmo, W.,
    5. Coroniti, R.,
    6. Trombino, G. E.,
    7. Romeo, F.,
    8. Ferraro, A.,
    9. Lanzino, M.,
    10. Aquila, S. et al.
    (2013). The estrogen receptor alpha is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness. Cell Cycle 12, 3405-3420. doi:10.4161/cc.26421
    OpenUrlCrossRefPubMed
  122. ↵
    1. Sohal, R. S. and
    2. Forster, M. J.
    (2014). Caloric restriction and the aging process: a critique. Free Radic. Biol. Med. 73, 366-382. doi:10.1016/j.freeradbiomed.2014.05.015
    OpenUrlCrossRefPubMed
  123. ↵
    1. Spaeth, J. M.,
    2. Hunter, C. S.,
    3. Bonatakis, L.,
    4. Guo, M.,
    5. French, C. A.,
    6. Slack, I.,
    7. Hara, M.,
    8. Fisher, S. E.,
    9. Ferrer, J.,
    10. Morrisey, E. E. et al.
    (2015). The FOXP1, FOXP2 and FOXP4 transcription factors are required for islet alpha cell proliferation and function in mice. Diabetologia 58, 1836-1844. doi:10.1007/s00125-015-3635-3
    OpenUrlCrossRefPubMed
  124. ↵
    1. Stroud, J. C.,
    2. Wu, Y.,
    3. Bates, D. L.,
    4. Han, A.,
    5. Nowick, K.,
    6. Paabo, S.,
    7. Tong, H. and
    8. Chen, L.
    (2006). Structure of the forkhead domain of FOXP2 bound to DNA. Structure 14, 159-166. doi:10.1016/j.str.2005.10.005
    OpenUrlCrossRefPubMed
  125. ↵
    1. Subauste, A. R. and
    2. Burant, C. F.
    (2007). Role of FoxO1 in FFA-induced oxidative stress in adipocytes. Am. J. Physiol. Endocrinol. Metab. 293, E159-E164. doi:10.1152/ajpendo.00629.2006
    OpenUrlAbstract/FREE Full Text
  126. ↵
    1. Sund, N. J.,
    2. Ang, S.-L.,
    3. Sackett, S. D.,
    4. Shen, W.,
    5. Daigle, N.,
    6. Magnuson, M. A. and
    7. Kaestner, K. H.
    (2000). Hepatocyte nuclear factor 3beta (Foxa2) is dispensable for maintaining the differentiated state of the adult hepatocyte. Mol. Cell. Biol. 20, 5175-5183. doi:10.1128/MCB.20.14.5175-5183.2000
    OpenUrlAbstract/FREE Full Text
  127. ↵
    1. Swindell, W. R.
    (2012). Dietary restriction in rats and mice: a meta-analysis and review of the evidence for genotype-dependent effects on lifespan. Ageing Res. Rev. 11, 254-270. doi:10.1016/j.arr.2011.12.006
    OpenUrlCrossRefPubMedWeb of Science
  128. ↵
    1. Takahashi, H.,
    2. Takahashi, K. and
    3. Liu, F.-C.
    (2009). Foxp genes, neural development, speech and language disorders. Adv. Exp. Med. Biol. 665, 117-129. doi:10.1007/978-1-4419-1599-3_9
    OpenUrlCrossRefPubMed
  129. ↵
    1. Talchai, C.,
    2. Xuan, S.,
    3. Lin, H. V.,
    4. Sussel, L. and
    5. Accili, D.
    (2012). Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150, 1223-1234. doi:10.1016/j.cell.2012.07.029
    OpenUrlCrossRefPubMedWeb of Science
  130. ↵
    1. Tang, Y.,
    2. Shu, G.,
    3. Yuan, X.,
    4. Jing, N. and
    5. Song, J.
    (2011). FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res. 21, 316-326. doi:10.1038/cr.2010.126
    OpenUrlCrossRefPubMedWeb of Science
  131. ↵
    1. Tank, E. M. H.,
    2. Rodgers, K. E. and
    3. Kenyon, C.
    (2011). Spontaneous age-related neurite branching in Caenorhabditis elegans. J. Neurosci. 31, 9279-9288. doi:10.1523/JNEUROSCI.6606-10.2011
    OpenUrlAbstract/FREE Full Text
  132. ↵
    1. Teramitsu, I.,
    2. Kudo, L. C.,
    3. London, S. E.,
    4. Geschwind, D. H. and
    5. White, S. A.
    (2004). Parallel FoxP1 and FoxP2 expression in songbird and human brain predicts functional interaction. J. Neurosci. 24, 3152-3163. doi:10.1523/JNEUROSCI.5589-03.2004
    OpenUrlAbstract/FREE Full Text
  133. ↵
    1. Titchenell, P. M.,
    2. Chu, Q.,
    3. Monks, B. R. and
    4. Birnbaum, M. J.
    (2015). Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat. Commun. 6, 7078. doi:10.1038/ncomms8078
    OpenUrlCrossRefPubMed
  134. ↵
    1. Toth, M. L.,
    2. Melentijevic, I.,
    3. Shah, L.,
    4. Bhatia, A.,
    5. Lu, K.,
    6. Talwar, A.,
    7. Naji, H.,
    8. Ibanez-Ventoso, C.,
    9. Ghose, P.,
    10. Jevince, A. et al.
    (2012). Neurite sprouting and synapse deterioration in the aging Caenorhabditis elegans nervous system. J. Neurosci. 32, 8778-8790. doi:10.1523/JNEUROSCI.1494-11.2012
    OpenUrlAbstract/FREE Full Text
  135. ↵
    1. Tuteja, G. and
    2. Kaestner, K. H.
    (2007a). SnapShot: forkhead transcription factors II. Cell 131, 192. doi:10.1016/j.cell.2007.09.016
    OpenUrlCrossRefPubMed
  136. ↵
    1. Tuteja, G. and
    2. Kaestner, K. H.
    (2007b). Snapshot: forkhead transcription factors I. Cell 130, 1160. doi:10.1016/j.cell.2007.09.005
    OpenUrlCrossRefPubMed
  137. ↵
    1. Tzivion, G.,
    2. Dobson, M. and
    3. Ramakrishnan, G.
    (2011). FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta 1813, 1938-1945. doi:10.1016/j.bbamcr.2011.06.002
    OpenUrlCrossRefPubMedWeb of Science
  138. ↵
    1. Updike, D. L. and
    2. Mango, S. E.
    (2006). Temporal regulation of foregut development by HTZ-1/H2A.Z and PHA-4/FoxA. PLoS Genet. 2, e161. doi:10.1371/journal.pgen.0020161
    OpenUrlCrossRefPubMed
  139. ↵
    1. Ustiyan, V.,
    2. Wang, I.-C.,
    3. Ren, X.,
    4. Zhang, Y.,
    5. Snyder, J.,
    6. Xu, Y.,
    7. Wert, S. E.,
    8. Lessard, J. L.,
    9. Kalin, T. V. and
    10. Kalinichenko, V. V.
    (2009). Forkhead box M1 transcriptional factor is required for smooth muscle cells during embryonic development of blood vessels and esophagus. Dev. Biol. 336, 266-279. doi:10.1016/j.ydbio.2009.10.007
    OpenUrlCrossRefPubMed
  140. ↵
    1. van der Sluis, M.,
    2. Vincent, A.,
    3. Bouma, J.,
    4. Korteland-Van Male, A.,
    5. Van Goudoever, J. B.,
    6. Renes, I. B. and
    7. Van Seuningen, I.
    (2008). Forkhead box transcription factors Foxa1 and Foxa2 are important regulators of Muc2 mucin expression in intestinal epithelial cells. Biochem. Biophys. Res. Commun. 369, 1108-1113. doi:10.1016/j.bbrc.2008.02.158
    OpenUrlCrossRefPubMedWeb of Science
  141. ↵
    1. Wan, H.,
    2. Kaestner, K. H.,
    3. Ang, S.-L.,
    4. Ikegami, M.,
    5. Finkelman, F. D.,
    6. Stahlman, M. T.,
    7. Fulkerson, P. C.,
    8. Rothenberg, M. E. and
    9. Whitsett, J. A.
    (2004). Foxa2 regulates alveolarization and goblet cell hyperplasia. Development 131, 953-964. doi:10.1242/dev.00966
    OpenUrlAbstract/FREE Full Text
  142. ↵
    1. Wang, M. and
    2. Gartel, A. L.
    (2011). The suppression of FoxM1 and its targets in breast cancer xenograft tumors by siRNA. Oncotarget 2, 1218-1226. doi:10.18632/oncotarget.359
    OpenUrlCrossRefPubMed
  143. ↵
    1. Wang, X.,
    2. Krupczak-Hollis, K.,
    3. Tan, Y.,
    4. Dennewitz, M. B.,
    5. Adami, G. R. and
    6. Costa, R. H.
    (2002). Increased hepatic forkhead box M1b (Foxm1b) levels in old-aged mice stimulated liver regeneration through diminished P27Kip1 protein levels and increased Cdc25B expression. J. Biol. Chem. 277, 44310-44316. doi:10.1074/jbc.M207510200
    OpenUrlAbstract/FREE Full Text
  144. ↵
    1. Wang, B.,
    2. Lin, D.,
    3. Li, C. and
    4. Tucker, P.
    (2003). Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J. Biol. Chem. 278, 24259-24268. doi:10.1074/jbc.M207174200
    OpenUrlAbstract/FREE Full Text
  145. ↵
    1. Wang, B.,
    2. Weidenfeld, J.,
    3. Lu, M. M.,
    4. Maika, S.,
    5. Kuziel, W. A.,
    6. Morrisey, E. E. and
    7. Tucker, P. W.
    (2004). Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131, 4477-4487. doi:10.1242/dev.01287
    OpenUrlAbstract/FREE Full Text
  146. ↵
    1. Wang, I.-C.,
    2. Zhang, Y.,
    3. Snyder, J.,
    4. Sutherland, M. J.,
    5. Burhans, M. S.,
    6. Shannon, J. M.,
    7. Park, H. J.,
    8. Whitsett, J. A. and
    9. Kalinichenko, V. V.
    (2010). Increased expression of FoxM1 transcription factor in respiratory epithelium inhibits lung sacculation and causes Clara cell hyperplasia. Dev. Biol. 347, 301-314. doi:10.1016/j.ydbio.2010.08.027
    OpenUrlCrossRefPubMed
  147. ↵
    1. Wang, I.-C.,
    2. Ustiyan, V.,
    3. Zhang, Y.,
    4. Cai, Y.,
    5. Kalin, T. V. and
    6. Kalinichenko, V. V.
    (2014a). Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.). Oncogene 33, 5391-5396. doi:10.1038/onc.2013.475
    OpenUrlCrossRefPubMed
  148. ↵
    1. Wang, J.,
    2. Zhu, C.-P.,
    3. Hu, P.-F.,
    4. Qian, H.,
    5. Ning, B.-F.,
    6. Zhang, Q.,
    7. Chen, F.,
    8. Liu, J.,
    9. Shi, B.,
    10. Zhang, X. et al.
    (2014b). Foxa2 suppresses the metastasis of hepatocellular carcinoma partially through matrix metalloproteinase-9 inhibition. Carcinogenesis 35, 2576-2583. doi:10.1093/carcin/bgu180
    OpenUrlAbstract/FREE Full Text
  149. ↵
    1. Webb, A. E.,
    2. Kundaje, A. and
    3. Brunet, A.
    (2016). Characterization of the direct targets of FOXO transcription factors throughout evolution. Aging Cell 15, 673-685. doi:10.1111/acel.12479
    OpenUrlCrossRef
  150. ↵
    1. Weigel, D.,
    2. Jürgens, G.,
    3. Küttner, F.,
    4. Seifert, E. and
    5. Jäckle, H.
    (1989). The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell 57, 645-658. doi:10.1016/0092-8674(89)90133-5
    OpenUrlCrossRefPubMedWeb of Science
  151. ↵
    1. Weinstein, D. C.,
    2. Ruiz I Altaba, A.,
    3. Chen, W. S.,
    4. Hoodless, P.,
    5. Prezioso, V. R.,
    6. Jessell, T. M. and
    7. Darnell, J. E., Jr..
    (1994). The winged-helix transcription factor HNF-3 beta is required for notochord development in the mouse embryo. Cell 78, 575-588. doi:10.1016/0092-8674(94)90523-1
    OpenUrlCrossRefPubMedWeb of Science
  152. ↵
    1. Wierstra, I.
    (2013). The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv. Cancer Res. 118, 97-398. doi:10.1016/B978-0-12-407173-5.00004-2
    OpenUrlCrossRefPubMedWeb of Science
  153. ↵
    1. Wierstra, I. and
    2. Alves, J.
    (2007). FOXM1, a typical proliferation-associated transcription factor. Biol. Chem. 388, 1257-1274. doi:10.1515/bc.2007.159
    OpenUrlCrossRefPubMedWeb of Science
  154. ↵
    1. Willcox, B. J.,
    2. Donlon, T. A.,
    3. He, Q.,
    4. Chen, R.,
    5. Grove, J. S.,
    6. Yano, K.,
    7. Masaki, K. H.,
    8. Willcox, D. C.,
    9. Rodriguez, B. and
    10. Curb, J. D.
    (2008). FOXO3A genotype is strongly associated with human longevity. Proc. Natl. Acad. Sci. USA 105, 13987-13992. doi:10.1073/pnas.0801030105
    OpenUrlAbstract/FREE Full Text
  155. ↵
    1. Wu, Q.-F.,
    2. Liu, C.,
    3. Tai, M.-H.,
    4. Liu, D.,
    5. Lei, L.,
    6. Wang, R.-T.,
    7. Tian, M. and
    8. Lü, Y.
    (2010). Knockdown of Foxm1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol. Sin 31, 361-366. doi:10.1038/aps.2010.4
    OpenUrlCrossRefPubMed
  156. ↵
    1. Xie, X.,
    2. Stubbington, M. J. T.,
    3. Nissen, J. K.,
    4. Andersen, K. G.,
    5. Hebenstreit, D.,
    6. Teichmann, S. A. and
    7. Betz, A. G.
    (2015). The regulatory T cell lineage factor Foxp3 regulates gene expression through several distinct mechanisms mostly independent of direct DNA binding. PLoS Genet. 11, e1005251. doi:10.1371/journal.pgen.1005251
    OpenUrlCrossRef
  157. ↵
    1. Yamaguchi, N.,
    2. Ito, E.,
    3. Azuma, S.,
    4. Honma, R.,
    5. Yanagisawa, Y.,
    6. Nishikawa, A.,
    7. Kawamura, M.,
    8. Imai, J.-I.,
    9. Tatsuta, K.,
    10. Inoue, J.-I. et al.
    (2008). FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochem. Biophys. Res. Commun. 365, 711-717. doi:10.1016/j.bbrc.2007.11.064
    OpenUrlCrossRefPubMedWeb of Science
  158. ↵
    1. Yang, J.-Y.,
    2. Zong, C. S.,
    3. Xia, W.,
    4. Yamaguchi, H.,
    5. Ding, Q.,
    6. Xie, X.,
    7. Lang, J.-Y.,
    8. Lai, C.-C.,
    9. Chang, C.-J.,
    10. Huang, W.-C. et al.
    (2008). Erk promotes tumorigenesis by inhibiting FOXO3A via MDM2-mediated degradation. Nat. Cell Biol. 10, 138-148. doi:10.1038/ncb1676
    OpenUrlCrossRefPubMedWeb of Science
  159. ↵
    1. Yao, K.-M.,
    2. Sha, M.,
    3. Lu, Z. and
    4. Wong, G. G.
    (1997). Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J. Biol. Chem. 272, 19827-19836. doi:10.1074/jbc.272.32.19827
    OpenUrlAbstract/FREE Full Text
  160. ↵
    1. Ye, D. Z. and
    2. Kaestner, K. H.
    (2009). Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in mice. Gastroenterology 137, 2052-2062. doi:10.1053/j.gastro.2009.08.059
    OpenUrlCrossRefPubMedWeb of Science
  161. ↵
    1. Ye, H.,
    2. Kelly, T. F.,
    3. Samadani, U.,
    4. Lim, L.,
    5. Rubio, S.,
    6. Overdier, D. G.,
    7. Roebuck, K. A. and
    8. Costa, R. H.
    (1997). Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol. Cell. Biol. 17, 1626-1641. doi:10.1128/MCB.17.3.1626
    OpenUrlAbstract/FREE Full Text
  162. ↵
    1. Yoshida, Y.,
    2. Wang, I. C.,
    3. Yoder, H. M.,
    4. Davidson, N. O. and
    5. Costa, R. H.
    (2007). The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 132, 1420-1431. doi:10.1053/j.gastro.2007.01.036
    OpenUrlCrossRefPubMed
  163. ↵
    1. Zaret, K. S.,
    2. Caravaca, J. M.,
    3. Tulin, A. and
    4. Sekiya, T.
    (2010). Nuclear mobility and mitotic chromosome binding: similarities between pioneer transcription factor FoxA and linker histone H1. Cold Spring Harb. Symp. Quant. Biol. 75, 219-226. doi:10.1101/sqb.2010.75.061
    OpenUrlAbstract/FREE Full Text
  164. ↵
    1. Zhang, L.,
    2. Rubins, N. E.,
    3. Ahima, R. S.,
    4. Greenbaum, L. E. and
    5. Kaestner, K. H.
    (2005). Foxa2 integrates the transcriptional response of the hepatocyte to fasting. Cell Metab. 2, 141-148. doi:10.1016/j.cmet.2005.07.002
    OpenUrlCrossRefPubMedWeb of Science
  165. ↵
    1. Zhang, H.,
    2. Ackermann, A. M.,
    3. Gusarova, G. A.,
    4. Lowe, D.,
    5. Feng, X.,
    6. Kopsombut, U. G.,
    7. Costa, R. H. and
    8. Gannon, M.
    (2006). The FoxM1 transcription factor is required to maintain pancreatic beta-cell mass. Mol. Endocrinol. 20, 1853-1866. doi:10.1210/me.2006-0056
    OpenUrlCrossRefPubMedWeb of Science
  166. ↵
    1. Zhang, Z.,
    2. Yang, C.,
    3. Gao, W.,
    4. Chen, T.,
    5. Qian, T.,
    6. Hu, J. and
    7. Tan, Y.
    (2015). FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer. Cancer Lett. 361, 240-250. doi:10.1016/j.canlet.2015.03.008
    OpenUrlCrossRef
  167. ↵
    1. Zhang, T.,
    2. Kim, D. H.,
    3. Xiao, X.,
    4. Lee, S.,
    5. Gong, Z.,
    6. Muzumdar, R.,
    7. Calabuig-Navarro, V.,
    8. Yamauchi, J.,
    9. Harashima, H.,
    10. Wang, R. et al.
    (2016). FoxO1 plays an important role in regulating beta-cell compensation for insulin resistance in male mice. Endocrinology 157, 1055-1070. doi:10.1210/en.2015-1852
    OpenUrlCrossRefPubMed
  168. ↵
    1. Zhu, H.
    (2016). Forkhead box transcription factors in embryonic heart development and congenital heart disease. Life Sci. 144, 194-201. doi:10.1016/j.lfs.2015.12.001
    OpenUrlCrossRef
  169. ↵
    1. Zhu, C.-P.,
    2. Wang, J.,
    3. Shi, B.,
    4. Hu, P.-F.,
    5. Ning, B.-F.,
    6. Zhang, Q.,
    7. Chen, F.,
    8. Chen, W.-S.,
    9. Zhang, X. and
    10. Xie, W.-F.
    (2015). The transcription factor FOXA2 suppresses gastric tumorigenesis in vitro and in vivo. Dig. Dis. Sci. 60, 109-117. doi:10.1007/s10620-014-3290-4
    OpenUrlCrossRef
  170. ↵
    1. Zuo, T.,
    2. Liu, R.,
    3. Zhang, H.,
    4. Chang, X.,
    5. Liu, Y.,
    6. Wang, L.,
    7. Zheng, P. and
    8. Liu, Y.
    (2007). FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest. 117, 3765-3773. doi:10.1172/jci32538
    OpenUrlCrossRefPubMedWeb of Science
Back to top

Keywords

 Download PDF

Email
PRIMER
Fox transcription factors: from development to disease
Maria L. Golson, Klaus H. Kaestner
Development 2016 143: 4558-4570; doi: 10.1242/dev.112672
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article navigation

Other journals from The Company of Biologists

Advertisement

An interview with Swathi Arur

Swathi Arur joined the team at Development as an Academic Editor in 2020. Her lab uses multidisciplinary approaches to understand female germline development and fertility. We met with her over Zoom to hear more about her life, her career and her love for C. elegans.

Jim Wells and Hanna Mikkola join our team of Editors

We are pleased to welcome James (Jim) Wells and Hanna Mikkola to our team of Editors. Jim joins us a new Academic Editor, taking over from Gordan Keller, and Hanna joins our team of Associate Editors. Find out more about their research interests and areas of expertise.

New funding scheme supports sustainable events

As part of our Sustainable Conferencing Initiative, we are pleased to announce funding for organisers that seek to reduce the environmental footprint of their event. The next deadline to apply for a Scientific Meeting grant is 26 March 2021.

Read & Publish participation continues to grow

“I’d heard of Read & Publish deals and knew that many universities, including mine, had signed up to them but I had not previously understood the benefits that these deals bring to authors who work at those universities.”

Professor Sally Lowell (University of Edinburgh) shares her experience of publishing Open Access as part of our growing Read & Publish initiative. We now have over 150 institutions in 15 countries and four library consortia taking part – find out more and view our full list of participating institutions.

Upcoming special issues

Imaging Development, Stem Cells and Regeneration
Submission deadline: 30 March 2021
Publication: mid-2021

The Immune System in Development and Regeneration
Guest editors: Florent Ginhoux and Paul Martin
Submission deadline: 1 September 2021
Publication: Spring 2022

Both special issues welcome Review articles as well as Research articles, and will be widely promoted online and at key global conferences.

Development presents...

Our successful webinar series continues into 2021, with early-career researchers presenting their papers and a chance to virtually network with the developmental biology community afterwards. Here, Michèle Romanos talks about her new preprint, which mixes experimentation in quail embryos and computational modelling to understand how heterogeneity in a tissue influences cell rate.

Save your spot at our next session:

10 March
Time: 9:00 (GMT)
Chaired by: Thomas Lecuit

Join our mailing list to receive news and updates on the series.